What are Datasets?

Datasets are defined file collections, whose access is governed by a Data Access Committee (DAC).

Total number of Datasets: 3634
Displaying 1 - 3634

Dataset Accessionsort ascending Description Technology Samples File Types
EGAD00010001433 Illumina HumanMethylation450 BeadChip Illumina 162
EGAD00010001430 Gene expression analysis from primary human JMML samples using Illumina Human HT-12 v4 Illumina_HumanHT-12_V4 15
EGAD00010001428 Cardio-Metabochip genotypes for IHIT cohort Illumina 2,791
EGAD00010001427 Cardio-Metabochip genotypes for B99 cohort Illumina 1,336
EGAD00010001422 1000G Phase 3 Imputed cases and controls from NSAID-induced PUD study Illumina Omni 2.5 676
EGAD00010001420 Read counts determined using HTSeq-count for the BBMRI BIOS Freeze 2 RNAseq data RNAseq 3,560
EGAD00010001418 HumanOmni25M-8v1-1 Illumina 24
EGAD00010001416 BBMRI - BIOS project - Freeze 2 - methylation Illumina Human Methylation 450k BeadChip 4,386
EGAD00010001414 Raw Array data from the PRAD-CA for ICGC DCC Release26 Affymetrix OncoScan FFPE Express 86
EGAD00010001412 Blood transcriptome from women participating in the Norwegian Women and Cancer study (NOWAC) Illumina HumanWG-6 version 3 or Illumina HumanHT-12 expression bead chip, combined on identical nucleotide universal identifier 920
EGAD00010001406 Breast cancer tissue and controls Exiqon 7th generation miRCURY LNA microRNA microarray system 149
EGAD00010001403 Gene expression read counts Illumina HiSeq2000 132
EGAD00010001400 Difference in gene expression values between case and control, log2 values. Blood transcriptome from women participating in the Norwegian Women and Cancer study (NOWAC) Post-genome Cohort taken up to eight years before brest cancer diagnosis. Illumina HumanWG-6 version 3 or Illumina HumanHT-12 expression bead chip, combined on identical nucleotide universal identifiers. Illumina HumanWG-6 467
EGAD00010001396 A discovery cohort of 856 adult survivors of pediatric ALL Genome-Wide Human SNP Array 6.0 - Thermo Fisher Scientific 856
EGAD00010001395 A replication cohort consisting of 1428 adult survivors of any non-ALL pediatric cancer Genome-Wide Human SNP Array 6.0 - Thermo Fisher Scientific 1,428
EGAD00010001390 HipSci - Battens Disease - Expression Array - July 2017 Illumina 1
EGAD00010001388 HipSci - Retinitis Pigmentosa - Expression Array - July 2017 Illumina 1
EGAD00010001386 HipSci - Macular Dystrophy - Expression Array - July 2017 Illumina 1
EGAD00010001384 HipSci - Bleeding and Platelet Disorders - Expression Array - July 2017 Illumina 1
EGAD00010001382 HipSci - Primary Immune Deficiency - Expression Array - July 2017 Illumina 1
EGAD00010001380 HipSci - Hypertrophic Cardiomyopathy - Expression Array - July 2017 Illumina 1
EGAD00010001378 HipSci - Congenital Hyperinsulinia - Expression Array - July 2017 Illumina 1
EGAD00010001376 HipSci - Alport Syndrome - Expression Array - July 2017 Illumina 1
EGAD00010001374 HipSci - Usher Syndrome - Expression Array - July 2017 Illumina 1
EGAD00010001372 HipSci - Kabuki Syndrome - Expression Array - July 2017 Illumina 1
EGAD00010001370 HipSci - Hereditary Spastic Paraplegia - Expression Array - July 2017 Illumina 1
EGAD00010001368 HipSci - Hereditary Cerebellar Ataxias - Expression Array - July 2017 Illumina 1
EGAD00010001366 HipSci - Battens Disease - Genotyping Array - July 2017 Illumina 1
EGAD00010001364 HipSci - Retinitis Pigmentosa - Genotyping Array - July 2017 Illumina 1
EGAD00010001362 HipSci - Macular Dystrophy - Genotyping Array - July 2017 Illumina 1
EGAD00010001360 HipSci - Bleeding and Platelet Disorders - Genotyping Array - July 2017 Illumina 1
EGAD00010001358 HipSci - Primary Immune Deficiency - Genotyping Array - July 2017 Illumina 1
EGAD00010001356 HipSci - Hypertrophic Cardiomyopathy - Genotyping Array - July 2017 Illumina 1
EGAD00010001354 HipSci - Congenital Hyperinsulinia - Genotyping Array - July 2017 Illumina 1
EGAD00010001352 HipSci - Alport Syndrome - Genotyping Array - July 2017 Illumina 1
EGAD00010001350 HipSci - Usher Syndrome - Genotyping Array - July 2017 Illumina 1
EGAD00010001348 HipSci - Kabuki Syndrome - Genotyping Array - July 2017 Illumina 1
EGAD00010001346 HipSci - Hereditary Spastic Paraplegia - Genotyping Array - July 2017 Illumina 1
EGAD00010001344 HipSci - Hereditary Cerebellar Ataxias - Genotyping Array - July 2017 Illumina 1
EGAD00010001342 HipSci - Monogenic Diabetes - Expression Array - July 2017 Illumina 1
EGAD00010001340 HipSci - Bardet-Biedl Syndrome - Expression Array - July 2017 Illumina 1
EGAD00010001334 HipSci - Monogenic Diabetes - Genotyping Array - July 2017 Illumina 1
EGAD00010001332 HipSci - Bardet-Biedl Syndrome - Genotyping Array - July 2017 Illumina 1
EGAD00010001330 HipSci - Healthy Normals - Expression Array - July 2017 Illumina 1
EGAD00010001328 HipSci - Healthy Normals - Genotyping Array - July 2017 Illumina 0
EGAD00010001326 Papuan Genotyping Illumina Multi-EthnicGlobal_A1 380
EGAD00010001323 Medulloblastoma methylation profiling Illumina Infinium HumanMethylation450 BeadChip 911
EGAD00010001319 Medulloblastoma methylation profiling Illumina Infinium HumanMethylation450 BeadChip 345
EGAD00010001315 Single cell transcriptomics of PBMCs of 47 donors from the Lifelines Deep cohort (general population, Northern part of the Netherlands). Cells of five or six different donors were pooled together in one sample pool, resulting in eight different sample pools. In total, 28.855 cells were captured and their transcriptomes were sequenced to an average depth of 74k. Genotype data was available for each donor, which allowed us to use the Demuxlet method that uses variable SNPs between the pooled individuals to determine which cell belongs to which individual. Since genotype information is lacking of 2 individuals, the transcriptome of only 45 individuals could be retrieved. Illumina HiSeq4000 45
EGAD00010001310 iOmics lipid data via mass spectrometry (MS) Agilent 1200 LC system 359
EGAD00010001309 iOmics genomic data using 2.5M and Exome array Illumina 2.5M and Illumina Exome array 323
EGAD00010001308 iOmics miRNA data via qPCR quantification patented mSMRT-qPCR miRNA assay (MIRXES) 351
EGAD00010001307 iOmics gene expression data using Expression Array Affymetrix Human Gene 1.0 ST Array 269
EGAD00010001301 Medulloblastoma expression profiling Affymetrix expression array 246
EGAD00010001300 Medulloblastoma expression profiling Affymetrix expression array 146
EGAD00010001298 primary human ACC and normal samples using 450K Illumina_450K 110
EGAD00010001296 DNA methylation analysis from primary human JMML and normal blood samples using 450K Illumina_450K 0
EGAD00010001294 Methylation data using 450K Illumina 450k 1,128
EGAD00010001292 Genotyping of hip osteoarthritis patients who have undergone total joint replacement Illumina InfiniumCoreExome-24v1-1_A 9
EGAD00010001291 Methylation profiling of hip osteoarthritis patients who have undergone total joint replacement Illumina HumanMethylation450K 27
EGAD00010001289 Resolving the Genetic Architecture of Aseptic Loosening After Total Hip Replacement Illumina InfiniumCoreExome-24v1-1_A 2,880
EGAD00010001287 Array methylation profiling of knee osteoarthritis patients who have undergone total joint replacement Illumina HumanMethylation450K 68
EGAD00010001285 Genotyping of knee osteoarthritis patients who have undergone total joint replacement Illumina InfiniumCoreExome-24v1-1_A 17
EGAD00010001283 Illumina HumanOmni5-Quad BeadChips Illumina 229
EGAD00010001281 SNP array dataset HUMANOMNIEXPRESS 50
EGAD00010001280 Transcriptome array dataset Affymetrix HG_U133_+2 25
EGAD00010001276 Expression profiling by Nanostring cancer pathway Nanostring cancer pathway 30
EGAD00010001275 Affymetrix GeneChip® Human Transcriptome Array 2.0 Affymetrix GeneChip® Human Transcriptome Array 2.0 34
EGAD00010001274 Expression profiling by Nanostring cancer immune Nanostring Cancer Immune 30
EGAD00010001273 Affymetrix GeneChip® Human Transcriptome Array 2.0 Affymetrix GeneChip® Human Transcriptome Array 2.0 34
EGAD00010001262 DNAm Case samples using Illumina Infinium 450K Illumina 450K array 32
EGAD00010001261 DNAm Case samples using Illumina Infinium 450K Illumina 450K array 33
EGAD00010001260 DNAm Case samples using Illumina Infinium 450K Illumina 450K array 33
EGAD00010001255 Autosomal STR genotypes using 15 Identifiler loci Applied Biosystems 990
EGAD00010001251 Epigenome of 36 rainforest hunther-gathering Baka of Cameroon by Illumina HumanMethylation450 array, used in the EGAS00001002226 study Illumina HumanMethylation450 38
EGAD00010001249 TGCT - GWAS loci Hi-C data Illumina HiSeq 2000 1
EGAD00010001246 UK TGCT controls samples using theInfinium OncoArray-500K BeadChip Infinium OncoArray-500K BeadChip 7,422
EGAD00010001243 UK TGCT control samples using the Infinium 1.2M array Illumina Infinium 1.2M array 4,946
EGAD00010001241 CN/LOH-profile of Translocation-negative FL_7 Affymetrix SNP 6.0 1
EGAD00010001240 CN/LOH-profile of Translocation-negative FL_1 Affymetrix SNP 6.0 1
EGAD00010001239 CN/LOH-profile of Translocation-negative FL_6 Affymetrix SNP 6.0 1
EGAD00010001238 CN/LOH-profile of Translocation-negative FL_2 Affymetrix SNP 6.0 1
EGAD00010001237 CN/LOH-profile of Translocation-negative FL_10 Affymetrix SNP 6.0 1
EGAD00010001236 CN/LOH-profile of Translocation-negative FL_4 Affymetrix SNP 6.0 1
EGAD00010001235 CN/LOH-profile of Translocation-negative FL_11 Affymetrix SNP 6.0 1
EGAD00010001234 CN/LOH-profile of Translocation-negative FL_9 Affymetrix SNP 6.0 1
EGAD00010001233 CN/LOH-profile of Translocation-negative FL_5 Affymetrix SNP 6.0 1
EGAD00010001232 CN/LOH-profile of Translocation-negative FL_8 Affymetrix SNP 6.0 1
EGAD00010001228 Primary and PDX SqCC samples using Infinium OmniExpress-24 Infinium_OmniExpress-24v1.0 24
EGAD00010001226 UK Biobank directly genotyped dataset Affymetrix 488,377
EGAD00010001225 UK Biobank autosomal imputation dataset Affymetrix 487,409
EGAD00010001223 Illumina Omni 2.5M SNPchip data (build37) of Egyptian samples from the Pagani et al. 2015 AJHG paper (doi: http://dx.doi.org/10.1016/j. ajhg.2015.04.019) Illumina HumanOmni2-5M-8v1-1_B 100
EGAD00010001221 Illumina Omni 2.5M SNPchip data (build37) of Ethiopian samples from the Pagani et al. 2015 AJHG paper (doi: http://dx.doi.org/10.1016/j. ajhg.2015.04.019) Illumina HumanOmni2-5_8v1_A 124
EGAD00010001218 Raw Array data from the CPCGene 200PG study Affymetrix OncoScan FFPE Express 248
EGAD00010001216 Melanoma cell lines CNV by SNP6 SNP6 22
EGAD00010001212 Genetic studies of pregnancy-related cardiometabolic disorders in Central Asian, Northern European, and Colombian populations Illumina HumanOmniExpress-12v1_J 1,207
EGAD00010001211 Inverse variance weighted fixed effect meta-analysis of three European GWAS studies of the offspring of Pre-eclampsia affected births (2658 Cases and 308267 Controls). 4
EGAD00010001209 Genome-wide SNP genotyping data for 1,235 western Africans by Illumina HumanOmniExpress-12 array, used in the EGAS00001002078 study Illumina HumanOmniExpress-12 1,235
EGAD00010001202 Human genotyping data for patients infected by hepatitis C virus Affymetrix UKBiobank Array 563
EGAD00010001200 Genotyping data from Indonesian sea nomad and surrounding populations Illumina Omni 5 105
EGAD00010001198 Case control samples using Infinium Omni2.5 Infinium Omni2.5M 274
EGAD00010001196 Raw Array data from the CPCGene BRCA study Affymetrix OncoScan FFPE Express 48
EGAD00010001192 Germline genotype data on 56,479 ovarian cancer cases and controls Illumina OncoArray 56,479
EGAD00010001188 This data set includes the following summary level data files used for the 13k analysis of T2D-GENES data: wes.variants.list: list of variants to keep for any analysis of the exomes data wes.assoc.samples.list: list of samples to keep for association analysis wes.assoc.variants.list: list of variants to keep for association analysis wes.sv.assoc.txt: single variant association analysis results wes.gene.ptv.variants.list.txt: list of protein truncating variants to use in gene-level analysis wes.gene.ptv.assoc.txt: results from gene-level tests of protein truncating variants wes.gene.nsstrict.variants.list.txt: list of NSstrict variants to use in gene-level analysis wes.gene.nsstrict.assoc.txt: results from gene-level tests of NSstrict variants wes.gene.nsbroad.variants.list.txt: list of NSbroad variants to use in gene-level analysis wes.gene.nsbroad.assoc.txt: results from gene-level tests of NSbroad variants wes.gene.ns.variants.list.txt: list of non synonymous variants to use in gene-level analysis wes.gene.ns.assoc.txt: results from gene-level tests of non synonymous variants 0
EGAD00010001187 This data set includes the following summary level data file used for the exome chip analysis: exome_chip.sv.assoc.txt: results from single variant association analysis in exome chip 0
EGAD00010001185 This data set includes the following summary level data files used for the GoT2D WGS analysis: wgs.assoc.samples.list: list of samples to keep for association analysis wgs.assoc.variants.list: list of variants to keep for association analysis wgs.sv.assoc.txt: single variant association results 0
EGAD00010001184 This data set includes the following summary level data file used for the imputation data: imputation.sv.assoc.txt: results from single variant association analysis in imputed samples 0
EGAD00010001179 Tissue samples using Illumina HumanOmniExpress-FFPE-12 v1.0 BeadChip Illumina HumanOmniExpress-FFPE-12 v1.0 BeadChip 22
EGAD00010001177 This dataset contains 61 tumors SNP-array dataset from 15 EGFR mutant lung adenocarcinoma patients. Illumina 61
EGAD00010001176 This dataset contains 15 control SNP-array dataset from 15 EGFR mutant lung adenocarcinoma patients. Illumina 15
EGAD00010001162 Oncotrack primary tumor samples using 450K. The dataset includes shared AF analysis files oncotrackDNAmAnalysis.R and oncotrackDNAmBetaScores.txt which were applied for both Oncotrack_450K_tumor (EGAD00010001162) and Oncotrack_450K_metastatic (EGAD00010001161) datasets. Illumina 450K 67
EGAD00010001161 Oncotrack metastatic samples using 450K. The shared AF analysis files oncotrackDNAmAnalysis.R and oncotrackDNAmBetaScores.txt which were applied for both Oncotrack_450K_tumor (EGAD00010001162) and Oncotrack_450K_metastatic (EGAD00010001161) datasets are included on Oncotrack_450K_tumor (EGAD00010001162) dataset. Illumina 450K 15
EGAD00010001158 Genotyping of additional Inflammatory Bowel Disease cases - 2014 (all samples) Illumina Human Core Exome 12v1-1_a 11,767
EGAD00010001157 Genotyping of additional Inflammatory Bowel Disease cases - 2014 (QC pass samples) Illumina Human Core Exome 12v1-1_a 9,247
EGAD00010001155 Crohn's disease DNA samples genotyped using UK Biobank Axiom array Axiom UKB 1,676
EGAD00010001153 Family Trios on aCGH 8x60K Agilent 8x60K 138
EGAD00010001149 HipSci - Monogenic Diebetes - Methylation Array - October 2016 Illumina 35
EGAD00010001147 HipSci - Healthy Normals - Genotyping Array - September 2016 Illumina 613
EGAD00010001145 HipSci - Bardet-Biedl Syndrome - Methylation Array - October 2016 Illumina 45
EGAD00010001143 HipSci - Healthy Normals - Expression Array - September 2016 Illumina 613
EGAD00010001141 Summary data from Meta-analysis of Genome-Wide-Association Studies for plasma levels of Coagulation Factor XI (FXI) 0
EGAD00010001139 HipSci - Healthy Normals - Methylation Array - October 2016 Illumina 181
EGAD00010001131 The 100 European-descent (EUB) and 100 African-descent (AFB) Belgians studied were genotyped for a total of 4,301,332 SNPs on the Illumina HumanOmni5-Quad BeadChips. Whole-exome sequencing was carried out for the same 200 individuals with the Nextera Rapid Capture Expanded Exome kit, on the Illumina HiSeq 2000 platform, with 100-bp paired-end reads. This kit delivers 62 Mb of genomic content per individual, including exons, untranslated regions (UTR), and microRNAs. Omni5 and exome datasets were merged, yielding a concordance rate between platforms of 99.93%. Illumina HumanOmni5-Quad and exome sequencing 200
EGAD00010001103 Genotype data from Chad, Lebanon, and Yemen Illumina HumanOmni2.5-8 v1.1 B 238
EGAD00010001102 Genotype data from Chad, Lebanon, and Yemen Illumina HumanOmni2.5-8 v1.2 A 126
EGAD00010001101 Genotype data from Chad, Lebanon, and Yemen Illumina HumanOmni2.5-8 v1.1 B 20
EGAD00010001099 Digital images of ovarian cancer metastases Aperio 127
EGAD00010001081 Summary statistics for Malaria Genomic Epidemiology Network, "A novel locus of resistance to severe malaria in a region of ancient balancing selection", Nature (2015) Illumina Omni 2.5M 11,657
EGAD00010001079 Affymetrix SNP6.0 array breast cancer data Affymetrix SNP6.0 66
EGAD00010001075 Argentine samples using 250K Illumina Exome 250K 391
EGAD00010001074 Rare CNVs from schizophrenia cases and controls Mulitple CNV platforms 0
EGAD00010001064 tumor-based gene expression from breast cancer cases IlluminaHuman HT12 173
EGAD00010001063 blood-based gene expression from breast cancer cases IlluminaHuman AWG-6 and HT12 173
EGAD00010001062 blood-based gene expression from breast cancer cases and age-matched controls IlluminaHuman AWG-6 and HT12 455
EGAD00010001058 APCDR AGV Project: Array data from 100 Ga-Adangbe. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B and HumanOmni2-5_8v1_A 100
EGAD00010001057 APCDR AGV Project: Array data from 88 Mandinka. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 88
EGAD00010001056 APCDR AGV Project: Array data from 100 Zulu. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B and HumanOmni2-5_8v1_A 100
EGAD00010001055 APCDR AGV Project: Array data from 100 Baganda. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B and HumanOmni2-5_8v1_A 100
EGAD00010001054 APCDR AGV Project: Array data from 74 Fula Illumina HumanOmni2-5_8v1_A 74
EGAD00010001053 APCDR AGV Project: Array data from 100 Banyarwanda. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B and HumanOmni2-5_8v1_A 100
EGAD00010001052 APCDR AGV Project: Array data from 100 Kalenjin. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B 100
EGAD00010001051 APCDR AGV Project: Array data from 97 Barundi. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 97
EGAD00010001050 APCDR AGV Project: Array data from 78 Wolof. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 78
EGAD00010001049 APCDR AGV Project: Array data from 99 Kikuyu. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B 99
EGAD00010001048 APCDR AGV Project: Array data from 79 Jola. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 79
EGAD00010001047 APCDR AGV Project: Array data from 107 Ethiopians (Amhara, Oromo, Somali; subset of Ethiopian Genome Project Genotyping). Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 107
EGAD00010001046 APCDR AGV Project: Array data from 86 Sotho. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 86
EGAD00010001045 APCDR AGV Project: Array data from 99 Igbo. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B 99
EGAD00010001043 WTCCC3 Anorexia Nervosa Infinium-HumanCoreExome Illumina HumanCoreExome-12v1-0_A and HumanCoreExome-24v1-0_A 925
EGAD00010001040 Methylation changes in OA patients with chronic exposure to cobalt and chromium Illumina HumanMethylation450 68
EGAD00010001034 WTCCC3 Anorexia Nervosa GWAS Illumina Human670-QuadCustom_v1_A 1,696
EGAD00010001032 RNA Expression using Illumina HT12 v3 Illlumina HT12 v3 153
EGAD00010001029 Summary statistics for a multi-cohort epigenome-wide association study. This includes summary statistics (effect-size, standard error, p-value) for 470,000 methylation markers. 0
EGAD00010001025 BLUEPRINT DNA methylation profiles of monocytes, T cells and B cells in type 1 diabetes-discordant monozygotic twins Illumina 450K 302
EGAD00010001012 BLUEPRINT DNA Methylation 450K data of mantle cell lymphoma Illumina HumanMethylation 450K 86
EGAD00010001006 Proteomics LC-MS MS dataset Liquid chromatography–mass spectrometry 8
EGAD00010001005 Illumina HumanCoreExome-12v1-1_A chip typing in a Greek adolescent population Illumina Human Core Exome 12v1.1 120
EGAD00010001004 WTCCC1 project samples from 1958 British Birth Cohort Infinium 550K 1,504
EGAD00010001003 This data set contains two data files. First data file (file name: PREDO_GA_EGA_methylation_data.csv) includes methylation data from 485512 sites accross human genome from 96 individuals acquired from Illumina 450K -chip. The other data file (file name: PREDO_GA_EGA_phenotypes.csv) contains the gestation ages and the genders of the 96 samples. Illumina 450K-chip (methylation data) 96
EGAD00010001001 Primary renal cell carcinoma (RCC), RCC metastases and cell lines by Illumina 450K Illumina 450K 62
EGAD00010000983 MeDIP-seq RPM chromsome BED files for Peripheral Blood from EPITWIN Project (Columns 4-4353 represent samples) MeDIP-seq 4,350
EGAD00010000965 Array data from 4778 individuals from general population of rural Uganda Illumina HumanOmni2.5-8 BeadChip 4,778
EGAD00010000963 Healthy volunteers recruited in Samoa HumanCore-24 BeadChip 24
EGAD00010000962 Healthy volunteers and missing phenotype individuals recruited in New Caledonia with higher density genotyping HumanOmniExpressExome-8 BeadChip 30
EGAD00010000961 Rheumatic heart disease cases recruited in Fiji HumanCore-24 BeadChip 535
EGAD00010000960 Definite and borderline rheumatic heart disease cases and patients with mild non-diagnostic valvulopathy recruited in Samoa HumanCore-24 BeadChip 126
EGAD00010000959 Healthy volunteers recruited in Fiji HumanCore-24 BeadChip 854
EGAD00010000958 Healthy volunteers recruited in Fiji with higher density genotyping HumanOmniExpressExome-8 BeadChip 32
EGAD00010000957 Rheumatic heart disease cases recruited in New Caledonia HumanCore-24 BeadChip 465
EGAD00010000956 Rheumatic heart disease cases recruited in New Caledonia with higher density genotyping HumanOmniExpressExome-8 BeadChip 34
EGAD00010000955 Rheumatic heart disease cases recruited in Fiji with higher density genotyping HumanOmniExpressExome-8 BeadChip 32
EGAD00010000954 Healthy volunteers recruited in New Caledonia HumanCore-24 BeadChip 356
EGAD00010000953 Healthy adult volunteers and newborns recruited in various countries across Oceania. HumanCore-24 BeadChip 937
EGAD00010000952 Where Are You From? samples types at 517K SNP loci Illumina HumanOmniExpress-24 BeadChip 598
EGAD00010000951 SNP array data for 668 cancer cell lines Illumina 2.5M 668
EGAD00010000950 WTCCC2 Bacteraemia Susceptibility (BS) smaples using Affymetrix 6.0 Affymetrix 6.0 4,924
EGAD00010000946 Human samples, 450k analysis Illumina 450k 127
EGAD00010000944 Genotyping data from Southeast Borneo individuals Illumina Human Omni Express Bead Chip-24 v1.0 41
EGAD00010000943 Sahel population study using 2.5M Illumina HumanOmni2.5 161
EGAD00010000942 Breast lesions assayed with Affymetrix SNP 6.0 Affymetrix SNP 6.0 125
EGAD00010000941 Gambian specimens without trachomatous scarring Illumina Omni 2.5 1,531
EGAD00010000940 Gambian specimens with trachomatous scarring WHO grade C2/C3 Illiumina Omni 2.5 1,531
EGAD00010000939 Illumina 1M SNP Array dataset Illumina 1M SNP Array 2
EGAD00010000938 mRNA Array Agilent 44K dataset Agilent 44K 16
EGAD00010000937 ACGH 180K dataset Agilent 180K 5
EGAD00010000936 Affymetrix Exon Array dataset Affymetrix GeneChip Human Exon 1.0 ST 2
EGAD00010000935 ACGH 244K dataset Agilent 244K 10
EGAD00010000934 Agilent miRNA dataset Agilent SurePrint Human miRNA Microarray 2
EGAD00010000929 WTCCC3_Primary Biliary Cirrhosis Replication Illumina ImmunoChip 2,981
EGAD00010000928 WTCCC3_Primary Biliary Cirrhosis Replication Post-QC Illumina ImmunoChip 2,861
EGAD00010000927 Subset 2 of osteoarthritis cases from the arcOGEN Consortium (http://www.arcogen.org.uk/) genotyped on HumanCoreExome-24v1-0 with consent for osteoarthritis studies only. Illumina HumanCoreExome-24v1-0 248
EGAD00010000926 Subset 1 of osteoarthritis cases from the arcOGEN Consortium (http://www.arcogen.org.uk/) genotyped on HumanCoreExome-12v1-1 with broader consent. Illumina HumanCoreExome-12v1-1 3,075
EGAD00010000925 Subset 1 of osteoarthritis cases from the arcOGEN Consortium (http://www.arcogen.org.uk/) genotyped on HumanCoreExome-12v1-0 with broader consent. Illumina HumanCoreExome-12v1-0 855
EGAD00010000924 Subset 2 of osteoarthritis cases from the arcOGEN Consortium (http://www.arcogen.org.uk/) genotyped on HumanCoreExome-12v1-1 with consent for osteoarthritis studies only. Illumina HumanCoreExome-12v1-1 991
EGAD00010000923 Subset 2 of osteoarthritis cases from the arcOGEN Consortium (http://www.arcogen.org.uk/) genotyped on HumanCoreExome-12v1-0 with consent for osteoarthritis studies only. Illumina HumanCoreExome-12v1-0 463
EGAD00010000922 Subset 1 of osteoarthritis cases from the arcOGEN Consortium (http://www.arcogen.org.uk/) genotyped on HumanCoreExome-24v1-0 with broader consent. Illumina HumanCoreExome-24v1-0 494
EGAD00010000921 samples using Affymetrix CYTOSCANHD CYTOSCANHD 12
EGAD00010000920 samples using Illumina HUMANOMNIEXPRESS HUMANOMNIEXPRESS 50
EGAD00010000919 samples using Illumina HUMANOMNI1QUAD HUMANOMNI1QUAD 2
EGAD00010000918 Understanding Society GWAS, samples that passed quality control, imputed to UK10K + 1000 Genomes combined reference panel Illumina HumanCoreExome-12v1-0 chip, UK10K + 1000 Genomes combined reference panel imputed 9,944
EGAD00010000917 399 tumors profiled using Agilent miRNA microarrays (Product Number G4872A, design ID 046064). The arrays are based on miRBase release 19.0 and 2006 human miRNAs are represented. 150 ng total RNA was used as input. Agilent miRNA microarrays 399
EGAD00010000916 BASIS breast cancer DNA methylation Illumina 450k Illumina 450k 457
EGAD00010000915 Affymetrix SNP6.0 breast cancer genome sequencing data Affymetrix SNP6.0 344
EGAD00010000913 SEA 660K Illumina 660K 3
EGAD00010000912 SEA 610K Illumina 610K 1
EGAD00010000911 HipSci - Embryonic Stem Cells - Genotyping Array - April 2016 Illumina 2
EGAD00010000910 HipSci - Embryonic Stem Cells - Expression Array - April 2016 Illumina 2
EGAD00010000909 HipSci - Embryonic Stem Cells - Methylation Array - April 2016 Illumina 2
EGAD00010000908 Illumina SNP-arrays for matching retinoblastoma-blood pairs and retinoblastoma cell lines. HumanOmni1 Quad BeadChip 132
EGAD00010000904 Genome-wide study of resistance to severe malaria in eleven worldwide populations:Kenya Illumina Omni 2.5M 3,865
EGAD00010000902 Genome-wide study of resistance to severe malaria in eleven worldwide populations:Gambia Illumina Omni 2.5M 5,594
EGAD00010000901 Russian Tuberculosis samples using Affymetrix 6.0 Affymetrix Genome-Wide Human SNP Array 6.0 Genotypes 11,937
EGAD00010000897 Infinium 450K in Rhabdomyosarcoma Infinium HumanMethylation450 BeadChip 53
EGAD00010000892 Healthy individuals from Italy Illumina 300
EGAD00010000891 Understanding Society GWAS, samples that passed quality control Illumina HumanCoreExome-12v1-0 9,944
EGAD00010000890 Understanding Society GWAS, all samples Illumina HumanCoreExome-12v1-0 10,463
EGAD00010000889 Gencode control samples using SNP6.0 SNP6.0 183
EGAD00010000887 Freeze 1 of the RP3 project Illumina Human Methylation 450k BeadChip 3,898
EGAD00010000886 samples using Affymetrix HG_U133_+2 Affymetrix HG_U133_+2 99
EGAD00010000881 Digital images of ovarian cancer sections Aperio 91
EGAD00010000875 CLL Expression Array Affymetrix U219 1,008
EGAD00010000874 Understanding Society Sequenom genotypes Sequenom 4,295
EGAD00010000872 Genotyped case and control sampes using HumanExome Beadchip 1,610
EGAD00010000871 CLL and normal B cell samples using 450K 226
EGAD00010000870 DNA methylation microarray Illumina_Infinium_HumanMethylation450 48
EGAD00010000869 RNA expression microarray Illumina_HumanHT-12v4 62
EGAD00010000868 Targeted bisulfite sequencing Illumina Bisulfite-Sequencing 16
EGAD00010000867 Expression Arrays Illumina beadarray 16
EGAD00010000865 MBDSEQ Illumina MBD-Sequencing 16
EGAD00010000863 H3K27Ac Illumina ChIP-Sequencing 16
EGAD00010000862 H3K27me3 Illumina ChIP-Sequencing 16
EGAD00010000860 Pol2 Illumina ChIP-Sequencing 16
EGAD00010000859 Smad3 Illumina ChIP-Sequencing 16
EGAD00010000858 Achalasia cases & controls 8,151
EGAD00010000854 WTCCC3 UK maternal cases of pre-eclampsia Illumina Human670-QuadCustom_v1 1,990
EGAD00010000853 VeraCode GoldenGate GT Assay technology 147
EGAD00010000850 BLUEPRINT DNA methylation profiles of monocytes, neutrophils and T cells from healthy donors Illumina 450K 525
EGAD00010000847 Genotyping using Affymetrix SNP6.0 49
EGAD00010000831 BLUEPRINT EpiMatch: harnessing epigenetics for hematopoietic stem cell transplantation Illumina Infinium HumanMethylation450 BeadChips 85
EGAD00010000829 Illumina Infinium 450K array data 70
EGAD00010000827 Illumina Infinium 450K array data 1
EGAD00010000823 Results of SNP arrays on synchronous CRC samples 1
EGAD00010000819 Summary statistics from meta-analysis for BP phenotypes 0
EGAD00010000817 HipSci - Monogenic Diabetes - Methylation Array - April 2015 0
EGAD00010000815 ATL tumor samples using Affymetrix 250K SNP array 1
EGAD00010000813 ATL tumor samples using Illumina 450K Methylation array 1
EGAD00010000811 ATL tumor samples using Illumina 610K SNP array 1
EGAD00010000807 Illumina HumanCoreExome genotyping data from the British Society for Surgery of the Hand Genetics of Dupuytren's Disease consortium (BSSH-GODD consortium) collection 4,201
EGAD00010000791 Illumina HumanOmni2.5-8 BeadChip 1
EGAD00010000790 ATRT expression Illumina Human HT6-v3 Array 41
EGAD00010000789 ATRT expression Illumina Human HT6-v3 Array 4
EGAD00010000787 Epigen-Brasil samples using HumanOmni2.5 6,487
EGAD00010000785 HipSci - Monogenic Diabetes - Expression Array - November 2014 0
EGAD00010000783 HipSci - Bardet-Biedl Syndrome - Expression Array - November 2014 0
EGAD00010000781 HipSci - Bardet-Biedl Syndrome - Methylation Array - April 2015 0
EGAD00010000779 HipSci - Monogenic Diabetes - Genotyping Array - November 2014 Illumina, unknown 9
EGAD00010000777 HipSci - Bardet-Biedl Syndrome - Genotyping Array - November 2014 0
EGAD00010000775 HipSci - Healthy Normals - Expression Array - November 2014 Illumina 580
EGAD00010000773 HipSci - Healthy Normals - Genotyping Array - November 2014 Illumina 580
EGAD00010000771 HipSci - Healthy Normals - Methylation Array - April 2015 0
EGAD00010000768 Replication data for HipSci normal samples using both HumanCoreExome-12_v1 and HumanOmni2.5-8 BeadChips 0
EGAD00010000766 We have established a mechanism for the collection of postal DNA samples from consenting National Joint Registry for England and Wales (NJR) patients and have carried out genotyping genome-wide in 903 patients with the condition Developmental Dysplasia of the Hip (DDH) on the Illumina CoreExome array 903
EGAD00010000764 Ovarian tumor samples using Illumina 0
EGAD00010000758 French glioma case germline genotypes using Illumina HumanExome-12v1_A array Illumina HumanExome-12v1_A 906
EGAD00010000756 French glioma control germline genotypes using Illumina HumanExome-12v1_A array Illumina HumanExome-12v1_A 699
EGAD00010000754 UK glioma case germline genotypes using Illumina HumanExome-12v1_A array Illumina HumanExome-12v1_A 596
EGAD00010000752 German glioma case germline genotypes using Illumina HumanExome-12v1_A array Illumina HumanExome-12v1_A 899
EGAD00010000750 German glioma control germline genotypes using Illumina HumanExome-12v1_A array Illumina HumanExome-12v1_A 2,391
EGAD00010000748 Genotyping using Illumina Human OmniExpress12v1.0 1
EGAD00010000744 Subset 2 of osteoarthritis cases genotyped on Illumina 610k from the arcOGEN Consortium (http://www.arcogen.org.uk/) with consent for osteoarthritis studies only. 2,326
EGAD00010000742 Subset 1 of osteoarthritis cases genotyped on Illumina610k from the arcOGEN Consortium (http://www.arcogen.org.uk/) with broader consent. 5,383
EGAD00010000740 Osteoarthritis cases genotyped on Illumina HumanOmniExpress from the arcOGEN Consortium (http://www.arcogen.org.uk/) with broader consent. 674
EGAD00010000738 Generation Scotland APOE data 18,336
EGAD00010000736 AAD case and control samples from UK and Norway 117
EGAD00010000730 WTCCC2 Psychosis Endophenotype samples from UK, Germany, Holland, Spain and Australia using the Affymetrix 6.0 array 1
EGAD00010000724 Pilot experiment on functional genomics in osteoarthritis (methyl) 0
EGAD00010000722 Pilot experiment on functional genomics in osteoarthritis (coreex) 1
EGAD00010000718 BLUEPRINT Gene expression of different B-cell subpopulations 42
EGAD00010000716 BLUEPRINT DNA Methylation of different B-cell subpopulations 35
EGAD00010000714 aplastic anemia samples tumor using 250K Affymetrix 250K Nsp-GTYPE 440
EGAD00010000712 ATRT genotyping 0
EGAD00010000710 ATRT genotyping blood 0
EGAD00010000708 Human samples typed on Illumina Omni 5M 0
EGAD00010000704 610k genotyping imputed on Hapmap 3 and 1000G Phase 1 CEU 714
EGAD00010000702 SNP-chip genotyping data for one proband in the DDD study (Ref : Carvalho AJHG 2015) 0
EGAD00010000698 PCGP INF ALL SNP6 0
EGAD00010000696 PCGP ETP ALL SNP6 0
EGAD00010000694 HCC array for cnv 55
EGAD00010000692 Genome-wide DNA methylation epigenotyping of African rainforest hunter-gatherers and neighbouring agriculturalists by Illumina HumanMethylation450 372
EGAD00010000690 Genome-wide SNP genotyping of African rainforest hunter-gatherers and neighbouring agriculturalists by Illumina HumanOmniExpress 160
EGAD00010000688 glioma normal samples using 250K 0
EGAD00010000686 glioma samples tumor using cytoscan 0
EGAD00010000684 glioma normal samples using cytoscan 0
EGAD00010000682 glioma samples tumor using 250K 0
EGAD00010000680 Tumor sample CGH arrays Agilent CGH array 4
EGAD00010000678 Tumor sample SNP arrays Illumina SNP array 11
EGAD00010000676 ELSA genome-wide genotypes, including estimated related individuals. There are 3 files: .fam, .bim, .bed 7,452
EGAD00010000674 ELSA genome-wide genotypes, excluding estimated related individuals. There are 3 files: .fam, .bim, .bed 7,412
EGAD00010000672 Purified plasma cells from bone marrow of Multiple myeloma patient unknown 1
EGAD00010000670 Purified plasma cells from bone marrow of Pooled healthy donors unknown 1
EGAD00010000668 Purified plasma cells from bone marrow of Monoclonal gammopathy of unknown significance patient unknown 1
EGAD00010000666 Purified plasma cells from tonsil of Healthy donor unknown 1
EGAD00010000664 Finnish population cohort genotyping_B 340
EGAD00010000662 Finnish population cohort genotyping 7,803
EGAD00010000658 DLBCL 148 SNP 6.0 Cohort 0
EGAD00010000656 Case samples using SNP 6.0 Array 0
EGAD00010000654 Control samples using SNP 6.0 Arrays 0
EGAD00010000652 Genotyped samples using Illumina HumanOmni2.5 402
EGAD00010000650 Genotypes from Omni2.5 chip 1,213
EGAD00010000648 nccRCC tumor/normal genotypes 0
EGAD00010000646 DNA methylation analysis of 35 prostate tumor and 6 normal prostate samples 41
EGAD00010000644 Affymetrix SNP6.0 cancer cell line exome sequencing data 1,022
EGAD00010000642 CLL Expression Array 144
EGAD00010000640 WTCCC2 Visceral Leishmaniasis samples from Sudanl using Illumina 670k 21
EGAD00010000638 WTCCC2 Visceral Leishmaniasis samples from Indial using Illumina 670k 97
EGAD00010000636 WTCCC2 Visceral Leishmaniasis samples from Brazil using Illumina 670k 119
EGAD00010000634 WTCCC2 People of the British Isles (POBI) samples using Affymetrix 6.0 array 2,930
EGAD00010000632 WTCCC2 People of the British Isles (POBI) samples using Illumina 1.2M array 2,912
EGAD00010000630 The TEENAGE study target population comprised adolescent students aged 13–15 years attending the first three classes of public secondary schools located in the wider Athens area of Attica. 436
EGAD00010000628 The TEENAGE study target population comprised adolescent students aged 13–15 years attending the first three classes of public secondary schools located in the wider Athens area of Attica. 0
EGAD00010000626 A new beta-globin mutation responsible of a beta-thalassemia (HbVar database ID 2928) was observed in 8 unrelated French families. The mutation carriers originated from Nord-Pas-de-Calais, a Northern French region where the chief town is Lille. 5 unrelated mutation carriers were genotyped for a set of 12 microsatellites from chromosome 11, around the beta-globin gene. Among the 5 mutation carriers, 4 were genotyped for 97 European Ancestry Informative SNPs (EAIMs). 37
EGAD00010000624 A new beta-globin mutation responsible of a beta-thalassemia (HbVar database ID 2928) was observed in 8 unrelated French families. The mutation carriers originated from Nord-Pas-de-Calais, a Northern French region where the chief town is Lille. 5 unrelated mutation carriers were genotyped for a set of 12 microsatellites from chromosome 11, around the beta-globin gene. Among the 5 mutation carriers, 4 were genotyped for 97 European Ancestry Informative SNPs (EAIMs). 0
EGAD00010000622 SNP array data for gastric cancer cell lines unknown 30
EGAD00010000620 Controls 3,683
EGAD00010000618 Ischemic stroke cases 3,682
EGAD00010000616 HumanOmni1-Quad genotyping array 230
EGAD00010000614 40 Druze Trios 120
EGAD00010000612 Celiac disease North Indian samples using Immunochip 0
EGAD00010000610 Samples from the Greek island of Crete, MANOLIS cohort 221
EGAD00010000608 SNP6 data for seminoma samples 8
EGAD00010000606 SNP6 data for matched normal samples 8
EGAD00010000604 DNA methylation data using Illumina 450K 2,195
EGAD00010000602 WTCCC2 Reading and Mathematics ability (RM) samples from UK using the Affymetrix 6.0 array 3,665
EGAD00010000600 Prostate Adenocarcinomas samples using 450K Illumina450K 80
EGAD00010000598 PCGP Ph-likeALL SNP6 1,724
EGAD00010000596 PCGP Ph-likeALL GEA 837
EGAD00010000594 SCOOP severe early-onset obesity cases 1,720
EGAD00010000584 WTCCC2 Glaucoma samples using Illumina 670k array 2,765
EGAD00010000580 Gencode control samples using 550K 217
EGAD00010000578 Gencode case samples using 550K 249
EGAD00010000574 Pleuropulmonary blastoma samples using 250K 14
EGAD00010000572 Imputation-based meta-analysis of severe malaria in Gambia. 2,870
EGAD00010000570 Imputation-based meta-analysis of severe malaria in Kenya. 3,343
EGAD00010000568 HipSci - Healthy Normals - Methylation Array - May 2014 0
EGAD00010000566 HipSci - Healthy Normals - Genotyping Array - May 2014 120
EGAD00010000564 HipSci - Healthy Normals - Expression Array - May 2014 120
EGAD00010000562 Medulloblastoma DNA methylation Illumina_HumanMethylation450 115
EGAD00010000560 SNP array of 7 HCCs and matched background liver in children with bile salt export pump deficiency Illumina HumanOmniExpress-12 v1. 14
EGAD00010000558 SNP 6.0 arrays of small cell lung cancer Affymetrix SNP 6.0 54
EGAD00010000556 SNP 6.0 arrays of small cell lung cancer 0
EGAD00010000554 SNP 6.0 arrays of small cell lung cancer 1,032
EGAD00010000552 Neuroblastoma samples 130
EGAD00010000546 SNP 6.0 arrays of carcinoid samples Affymetrics_SNP_6.0- 74
EGAD00010000544 Cusihg's syndrome tumor samples using 250K Affymetrix 250K Nsp-GTYPE 16
EGAD00010000542 Cusihg's syndrome normal samples using 250K Affymetrix 250K Nsp-GTYPE 16
EGAD00010000538 28 unlinked autosomal microsatellite loci for 20 African and 4 philippine populations Applied Biosystems 3100 automated sequencer-GeneMarker v.1.6 (Softgenetics) 1,702
EGAD00010000536 21 unlinked autosomal microsatellite loci for 30 Central Asian populations Applied Biosystems 3100 automated sequencer-GeneMarker v.1.6 (Softgenetics) 1,702
EGAD00010000534 Illumina HumanMethylation450 BeadChip 0
EGAD00010000532 Illumina Human Omni1-Quad SNP genotyping array 0
EGAD00010000528 Illumina HumanHT-12 v4 array 0
EGAD00010000526 SNP 6.0 arrays of small cell lung cancer Affymetrics_SNP_6.0- 63
EGAD00010000522 Samples from the Greek island of Crete, MANOLIS cohort HumanOmniExpress-12 v1.1 BeadChip-GenCall 1,364
EGAD00010000520 Healthy volunteer collection of European Ancestry Illumina OmniExpress v1.0-Illumina GenomeStudio 144
EGAD00010000518 Samples from the Greek island of Crete, MANOLIS cohort HumanExome_12v1.1_A -GenCall, zCall 1,280
EGAD00010000516 Samples from the Pomak Villages in Greece, Pomak isolate HumanExome_12v1.1_A -GenCall, zCall 1,046
EGAD00010000514 Case samples using SNP 6.0 Array GenomeWideSNP_6-BirdseedV2 12
EGAD00010000512 Case samples using HumanOmni1-Quad GenomeWideSNP_6-BirdseedV2 12
EGAD00010000510 Matched control samples using HumanOmni1-Quad GenomeWideSNP_6-BirdseedV2 12
EGAD00010000508 Matched control samples using SNP 6.0 Array GenomeWideSNP_6-BirdseedV2 12
EGAD00010000506 WTCCC2 BO (Barretts oesophagus) samples Illumina_670k-Illuminus 1,991
EGAD00010000504 Control samples using SNP Array 6.0 Affymetrix_U133plus2- 35
EGAD00010000502 Case samples using SNP Array 6.0 Affymetrix_U133plus2- 35
EGAD00010000500 Case samples using U133 Plus 2.0 Array Affymetrix_U133plus2- 35
EGAD00010000498 Affymetrix SNP6.0 genotype data for prostate cancer patients Affymetrix_SNP6- 18
EGAD00010000496 Genome-wide SNP genotyping of African rainforest hunter-gatherers and neighbouring agriculturalists Illumina HumanOmni1-Quad-Illumina GenomeStudio 260
EGAD00010000494 Controls_Human660W-Quad_v1_A Illumina_Human660W-Quad_v1_A-Not supplied 4
EGAD00010000492 Cases_Human660W-Quad_v1_A Illumina_Human660W-Quad_v1_A-Not supplied 4
EGAD00010000490 Affymetrix Genome-Wide Human SNP Array 6.0 data Affymetrix 6.0- 19
EGAD00010000488 Chondroblastoma case sample genotype using Affymetrix SNP6.0 Affymetrix_SNP6- 7
EGAD00010000486 ccRCC case samples using expression array Agilent Human Whole Genome 4x44k v2 - Feature Extraction 101
EGAD00010000484 ccRCC control samples using 250K Nsp Affymetrix_250K(Nsp) - gtype 234
EGAD00010000482 ccRCC case samples using methylation array Illumina Infinium HumanMethylation 450K - GenomeStudio 1
EGAD00010000480 ccRCC case samples using 250K Nsp Affymetrix_250K(Nsp) - gtype 240
EGAD00010000478 blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 3 (CC3) Illumina 118
EGAD00010000476 blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 1 (CC1) Illumina 110
EGAD00010000474 blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 2 (CC2) Illumina 98
EGAD00010000472 CLL Expression Array Affymetrix U219 219
EGAD00010000470 CLL Expression Array GPL570 20
EGAD00010000468 Uveal melanoma matched Tumour and blood samples Illumina HumanOmni2.5 24
EGAD00010000466 Down syndrome CNV genotyping data NimbleGen 135K aCGH - NimbleScan 108
EGAD00010000464 Down syndrome SNP genotyping data Illumina 550K - Illumina Genome Studio 338
EGAD00010000462 SJLGG Case samples using Gene Expression Array Affymetrix_U133v2 75
EGAD00010000460 GENCORD2 DNA methylation 294
EGAD00010000458 Controls using 450K DNA methylation 151
EGAD00010000456 Leukemia samples using 450K DNA methylation 800
EGAD00010000452 Chondrosarcoma case sample genotype using Affymetrix SNP6.0 Affymetrix_SNP6 36
EGAD00010000450 Genome Wide Genotype Data Illumina Human Custom 1,2M and Human 610 Quad Custom arrays 758
EGAD00010000448 Macrophage Gene Expression Illumina Human-Ref-8 v3 beadchip 758
EGAD00010000446 Monocyte Gene Expression Illumina Human-Ref-8 v3 beadchip 758
EGAD00010000444 Agilent ncRNA 60k txt files Agilent ncRNA 60k 1,480
EGAD00010000442 Affymetrix SNP 6.0 CEL files Affymetrix_SNP6_raw 1,302
EGAD00010000440 Segmented copy number data Affymetrix_SNP6_raw 1,302
EGAD00010000438 Normalized miRNA expression data Agilent ncRNA 60k 1,480
EGAD00010000436 Illumina HT 12 IDAT files Illumina HT 12 1,302
EGAD00010000434 Normalised mRNA expression Illumina HT 12 1,302
EGAD00010000429 DNA methylation analysis of 4 primary lymphoma samples HumanMethylation450k Bead Chip - Genome Studio 4
EGAD00010000427 DNA methylation analysis of 4 peripheral blood samples HumanMethylation450k Bead Chip - Genome Studio 4
EGAD00010000425 Han Chinese samples using Immunochip HanChinese_Immunochip 192
EGAD00010000423 Han Chinese samples using Illumina OMNIExpress (controls) Illumina OMNIExpress 213
EGAD00010000421 Han Chinese samples using Affymetrix (controls) Affymetrix_6.0 187
EGAD00010000419 Han Chinese samples using Affymetrix (cases) Affymetrix_6.0 62
EGAD00010000417 Han Chinese samples using Illumina OMNIExpress (cases) Illumina OMNIExpress 62
EGAD00010000395 Myeloma case sample genotype using Affymetrix SNP6.0 Affymetrix_SNP6 19
EGAD00010000391 Cambridge control samples using a 660K genotyping chip from Illumina Illumina Human 660K Quad BeadChips - Illuminus 232
EGAD00010000389 Cambridge control samples using a 24k expression array from Illumina Illumina Human-Ref 8 v3.0 expression array 395
EGAD00010000387 Cambridge control samples using a 1.2M genotyping chip from Illumina Illumina Human 1.2M Duo custom BeadChips v1 - Genome Studio 188
EGAD00010000385 MRCA sample using 300K Illumina 300K - GenomeStudio 394
EGAD00010000383 MRCA sample using 100K Illumina 100K - GenomeStudio 394
EGAD00010000381 MRCE sample using 300K Illumina 300K - GenomeStudio 543
EGAD00010000379 DNA methylation analysis of 2 peripheral blood samples HumanMethylation450k Bead Chip - Genome Studio 2
EGAD00010000377 DNA methylation analysis of 6 primary lymphoma samples HumanMethylation450k Bead Chip - Genome Studio 6
EGAD00010000371 Case and control samples (Genotypes) Infinium_370k - GenomeStudio 170
EGAD00010000300 Summary statistics from Haemgen RBC GWAS Illumina, Affymetrix, Perlegen 1
EGAD00010000298 All cases and controls (Hap300) 13,761
EGAD00010000296 1958BC control samples only (Hap550) 2,224
EGAD00010000294 1958BC control samples only (Hap300) 2,436
EGAD00010000292 All cases and Finnish, Dutch, Italian control samples (Hap300) 10,339
EGAD00010000290 NBS control samples only (Hap550) 2,276
EGAD00010000288 All cases and Finnish, Dutch, Italian control samples (Hap550) 6,313
EGAD00010000286 All cases and controls (Hap550) Illumina (various) 11,950
EGAD00010000284 NBS control samples only (Hap300) Illumina (Various) 2,500
EGAD00010000282 Pharmacogenomic response to Statins samples (Genotypes/Phenotypes) Affymetrix 6.0 - CHIAMO 4,134
EGAD00010000280 CLL Expression array Affymetrix snp 6.0 4
EGAD00010000278 SCLC matched normal genotypes Illumina_2.5M 51
EGAD00010000276 SCLC tumor genotypes Illumina_2.5M 56
EGAD00010000274 Colon matched tumour samples Illumina_2.5M 74
EGAD00010000272 Colon tumour samples Illumina_2.5M 75
EGAD00010000270 Metabric breast cancer samples (Images) Aperio image - H&E stained tissue_section 564
EGAD00010000268 Metabric breast cancer samples (Expression raw data) Illumina HT 12 543
EGAD00010000266 Metabric breast cancer samples (Genotype raw data) Affymetrix SNP 6.0 543
EGAD00010000264 WTCCC2 project samples from Ischaemic Stroke Cohort Illumina_670k - Illuminus 4,205
EGAD00010000262 WTCCC2 project Schizophrenia (SP) samples Affyemtrix 6.0 - CHIAMO 3,019
EGAD00010000260 PNET genotyping Illumina OmniQuad 2.5 - CNVpartition 77
EGAD00010000254 CLL Methylation Arrays Illumina HumanMethylation450 165
EGAD00010000252 CLL Expression Arrays Affymetrix U219 137
EGAD00010000250 NBS control samples Illumina ImmunoBeadChip - Illuminus, GenoSNP 3,030
EGAD00010000248 1958BC control samples Illumina ImmunoBeadChip - Illuminus, GenoSNP 6,812
EGAD00010000246 Coeliac disease cases and control samples. (1958BC samples excluded) Illumina ImmunoBeadChip - Illuminus, GenoSNP 10,758
EGAD00010000238 CLL Expression array Affymetrix GeneChip Human Genome U133 plus 2.0 64
EGAD00010000236 WTCCC2 samples from Coronary Artery Disease Cohort - Illuminus, GenoSNP 3,125
EGAD00010000234 WTCCC2 samples from 1958 British Birth Cohort Illumina HumanExome-12v1_A-GenCall, zCall 12,241
EGAD00010000232 WTCCC2 samples from Type 2 Diabetes Cohort - Illuminus 2,975
EGAD00010000230 WTCCC2 samples from Hypertension Cohort - Illuminus 2,943
EGAD00010000220 Ovarian & matched normal (Genotypes) Complete Genomics - CG Build 1.4.2.8 2
EGAD00010000217 Segmented (HMM) copy number aberrations (CNA); discovery set Affymetrix SNP 6.0 997
EGAD00010000216 Segmented (CBS) copy number variants (CNV); validation set Affymetrix SNP 6.0 995
EGAD00010000215 Segmented (CBS) copy number aberrations (CNA); validation set Affymetrix SNP 6.0 995
EGAD00010000214 Segmented (CBS) copy number variants (CNV); discovery set Affymetrix SNP 6.0 997
EGAD00010000213 Segmented (CBS) copy number aberrations (CNA); discovery set Affymetrix SNP 6.0 997
EGAD00010000212 Normalized expression data; normals Illumina HT 12 144
EGAD00010000211 Normalized expression data; validation set Illumina HT 12 995
EGAD00010000210 Normalized expression data; discovery set Illumina HT 12 997
EGAD00010000202 Case samples (Illumina_660K & Illumina_670K) Illumina_660K/Illumina_670K 1,478
EGAD00010000164 Affymetrix 6.0 CEL files Affymetrix SNP 6.0 1,992
EGAD00010000162 Illumina HT 12 IDATS Illumina HT 12 2,136
EGAD00010000160 Illumina HT 12 IDATS Illumina HT 12 1,001
EGAD00010000158 Affymetrix 6.0 cel files Affymetrix SNP 6.0 1,001
EGAD00010000150 WTCCC2 project samples from Ankylosing spondylitis Cohort Illumina_670k - Illuminus 2,005
EGAD00010000148 tumour samples using Affymetrix Genome-Wide SNP6.0 arrays Affymetrix_GenomeWide_SNP6.34 104
EGAD00010000144 Healthy volunteer collection of European Ancestry Illumin OmniExpress v1.0 - Illumina GenomeStudio 288
EGAD00010000130 Cerebellar ataxia, mental retardation, and disequilibrium syndrome (CAMRQ) samples Illumina 300 Duo V2 - Bead Studio, Illumina 2
EGAD00010000124 Psoriasis cases as part of WTCCC2 phase 2 Illumina_670k - Illuminus 2,622
EGAD00010000096 DBA case samples using 250K Nsp Affymetrix_250K(Nsp) - gtype 27
EGAD00010000052 Monozygotic twins that are discordant for schizophrenia (Genotyping) CompleteGenomics build 1.4.2.8 - CG Build 1.4.2.8 36
EGAD00010000051 Cell line derived from microdissected primary pancreatic ductal adenocarcinoma tissues Affymetrix SNP 6.0 15
EGAD00010000050 Matched tumor-negative pancreas tissues Affymetrix SNP 6.0 15
EGAD00001003800 Whole Exome Sequencing was performed in a dilution series containing known amounts of human and mouse DNA, 3x 100% human 0% mouse, 2x 90/10, 3x 50/50, 2x 25/75 and 3x 0/100. A set of breast cancer clinical samples, matched normal tissue and matched PDTXs (total number = 14) were also analysed. Paired-end 75bp sequences for the dilution series and paired-end 125bp for the clinical samples were obtained on Illumina HiSeq2500; fastq files are provided. A triplicate analysis of the transcriptome using RNA-seq was also performed for the Universal Human RNA Reference and the Universal Mouse RNA Reference samples. Paired-end 150bp fastq files obtained on Illumina HiSeq4000 are provided. Illumina HiSeq 2500;ILLUMINA, Illumina HiSeq 4000;ILLUMINA 12
EGAD00001003798 October 2017 data update (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500;ILLUMINA 28
EGAD00001003797 This dataset contains WES data (.bam files) and associated phenotype information from 10 patients included in our microbiome study who went on to anti PD-1 immunotherapy for the treatment of metastatic melanoma at the University of Texas MD Anderson Cancer Center. Both tumor and matching germ line normal were sequenced on each patient using Illumina HiSeq 2500. The average coverage was 283X in tumors and 135X in germline (tumor+germline overall:209, Range: 0-1552). Illumina HiSeq 2500;ILLUMINA 20
EGAD00001003795 This dataset includes Nimblegen SeqCap EZ Exome v3 data for each lesion of three patients with multicentric glioma. For two patients, each lesion was sequenced along with whole blood. For a third patient, 3 pieces from the right lesion and 4 pieces from the left were sequenced along with whole blood. In each case BAM files that have been aligned with BWA mem alignment are available. 15
EGAD00001003794 8
EGAD00001003793 By differential gene expression analysis followed by protein expression and functional studies, we define that the naive T cells having divided the least since thymic emigration express complement receptors (CR1 and CR2) known to bind complement C3b- and C3d-decorated microbial products and, following activation, produce IL-8 (CXCL8), a major chemoattractant for neutrophils in bacterial defense. We also observed an IL-8–producing memory T cell subpopulation coexpressing CR1 and CR2 and with a gene expression signature resembling that of RTEs. JCI Insight. 2017;2(16):e93739. https://doi.org/10.1172/jci.insight.93739 Illumina HiSeq 2500;ILLUMINA 24
EGAD00001003792 The dataset for High Grade Serous Ovarian Carcinomas Originate in the Fallopian Tube includes 46 bam files from next-generation sequencing on the Illumina HiSeq2500. The samples analyzed include multiple lesions from nine patients, five with high grade serous ovarian carcinoma and four who are BRCA-carriers. Illumina HiSeq 2500;ILLUMINA 46
EGAD00001003791 The SAHGP characterises the genomes of 24 individuals (8 Coloured and 16 black southeastern Bantu-speakers) using deep whole genome sequencing (WGS). 3
EGAD00001003790 RNA seq reads constituting of FASTQ paired end reads from 5 FHD/FHDL patients Illumina HiSeq 2000;ILLUMINA 13
EGAD00001003789 Exome reads constituting of FASTQ paired end reads from 5 FHD/FHDL patients Illumina HiSeq 2000;ILLUMINA 16
EGAD00001003788 Whole Exome Sequencing of 9 Colorectal Cancer (CRC) samples performed on Illumina HiSeq4000 consisting of aligned paired reads. RNAseq data sequenced on Illumina NextSeq500 consisting of FASTQ single reads from 3 CRC colon samples. A total of 12 samples from five patients (we matched normal tissue or pbmc and tumors) were sequenced on Illumina NextSeq500. NextSeq 500;ILLUMINA, Illumina HiSeq 4000;ILLUMINA 24
EGAD00001003787 BBMRI - BIOS project - Freeze 2 - Fastq files - GoNL samples Illumina HiSeq 2000;ILLUMINA 420
EGAD00001003786 BBMRI - BIOS project - Freeze 2 - Bam files - GoNL samples Illumina HiSeq 2000;ILLUMINA 420
EGAD00001003785 BBMRI - BIOS project - Freeze 2 - Fastq files - unrelated samples Illumina HiSeq 2000;ILLUMINA 3,559
EGAD00001003784 BBMRI - BIOS project - Freeze 2 - Bam files - unrelated samples Illumina HiSeq 2000;ILLUMINA 3,559
EGAD00001003783 Recent studies using next-generation sequencing strategies have described the landscape of genetic alterations in diffuse large B-cell lymphoma (DLBCL). However, little is known about the clinical relevance of recurrent mutations and copy number alterations and their transcriptional footprints. This study examines the frequency, interaction and clinical impact of recurrent genetic aberrations in DLBCL using high-resolution technologies in a large population-based cohort. 324
EGAD00001003782 When available (25 primary MDS, 12 MDS/MPN, and 6 AML-MRC cases), high quality RNA (stranded-total) was submitted for RNA-seq. RNA was extracted from bulk myeloid cells which was used as the tumor population. Files uploaded are mapped BAM files. Illumina HiSeq 2000;ILLUMINA 43
EGAD00001003781 Paired whole exome sequencing for 32 primary MDS, 14 MDS/MPN, and 8 AML-MRC cases (total = 54). Normal comparator genomic DNA was extracted from lymphocytes purified by flow cytometry. Bulk myeloid cells were used as a source of tumor gDNA. Files uploaded are mapped BAM files. Illumina HiSeq 2000;ILLUMINA 94
EGAD00001003780 RNA-seq data obtained from directed differentiation of a subset of FiPSCs and BiPSCs cell lines towards islet-like cells. RNA was collected at two key developmental stages: definitive endoderm (DE) and pancreatic progenitors (PP). Illumina HiSeq 2500;ILLUMINA 16
EGAD00001003778 Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003769 This dataset is a time-series of EGFR-mutant NSCLC clinical specimens from an individual patient profiled using tumor-based whole exome sequencing and the data is in BAM format. DNA was extracted from FFPE for primary tumor and frozen tumor tissue samples and matched non-tumor tissue using the Qiagen Allprep DNA/RNA Mini Kit.  The library preparation protocol was based on the Agilent SureSelect Library Prep and Capture System. DNA was resuspended in a low TE buffer and sheared (Duty Cycle 5%; Intensity 175; Cycles/Burst: 200; Time: 300s, Corvaris S2 Utrasonicator).  Bar-coded exome libraries were prepared using the Agilent Sure Select V5 library kit per manfucaturer’s specifications. The libraries were run on the HiSeq2500. Raw paired end reads (100bp) in FastQ format generated by the Illumina pipeline were aligned to the full hg19 genomic assembly obtained from USCS, gencode 14, using bwa version 0.7.12. Picard tools version 1.117 was used to sort, remove duplicate reads and generate QC statistics. Tumor DNA was sequenced to median depth of 303X (range 114.39-383.41) and the matched germline DNA to average depth of 231.65. Illumina HiSeq 2500;ILLUMINA 8
EGAD00001003762 Whole Exome sequencing of paediatric High Grade Gliomas Illumina HiSeq 2000;ILLUMINA 100
EGAD00001003761 This dataset contains fastq files with Whole genome sequencing data for the CPC-Gene Project. Data from each sample was generated using multiple whole genome libraries and sequenced across multiple runs Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA, unspecified;ILLUMINA 617
EGAD00001003760 There are 88 paired samples from HCC patients including tumors and matched adjacent normal tissues which were sequencing by Illumina HiSeq 2000 platform. Illumina HiSeq 2000;ILLUMINA 176
EGAD00001003759 ATAC-seq data for 5 non-diabetic human pancreatic islet samples Illumina HiSeq 2500;ILLUMINA 5
EGAD00001003758 BBMRI - BIOS project - Freeze 2 - Bam files Illumina HiSeq 2000;ILLUMINA 3,686
EGAD00001003757 BBMRI - BIOS project - Freeze 2 - Fastq files Illumina HiSeq 2000;ILLUMINA 3,686
EGAD00001003755 This dataset provides whole genome sequencing data of normal/tumors pairs from 9 patients with uterine or ovarian carcinosarcoma using the HiSeq 2000 sequencing system. It includes 27 samples (9 normals, 16 uterine tumors and 2 ovarian tumors). Through separate whole genome sequencing of carcinomatous and sarcomatoid components, we analyse and compare the genomic alterations of these components. Illumina HiSeq 2000;ILLUMINA 27
EGAD00001003754 structural variant calls from Delly, vcf format 37
EGAD00001003753 single nucleotide variant calls from somatic sniper, vcf format. input for subclonal reconstruction 20
EGAD00001003752 single nucleotide variant calls from somatic sniper, vcf format 34
EGAD00001003751 Whole genome sequencing data for primary tumors, matching control material from blood and their corresponding organoid. Whole transcriptome data for organoids. HiSeq X Ten;ILLUMINA, NextSeq 500;ILLUMINA 102
EGAD00001003750 This is the first whole exome sequencing analysis of a primary meningeal melanocytic tumour (MMT) alongside the patients germline. Here we report the CRAM files from the tumour and germline. Illumina HiSeq 2500;ILLUMINA 2
EGAD00001003748 Sequencing of B-cell receptor repertoires in healthy individuals and patients with chronic lymphocytic leukemia. 1) This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/ This dataset contains all the data available for this study on 2017-09-13. Illumina MiSeq;ILLUMINA 387
EGAD00001003747 Optimisation of ex vivo Memory B cell Expansion/Differentiation for Interrogation of Rare Peripheral Memory B Cell Subset Responses 1) This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/ This dataset contains all the data available for this study on 2017-09-13. Illumina MiSeq;ILLUMINA 38
EGAD00001003746 Sequencing was performed using OncoPanel v.2 (OPv2), an Agilent SureSelect custom designed bait set consisting of the coding regions of 504 genes, previously linked to human cancer. Sequencing wa sperformed on an Illumina HiSeq 2500. 14 highly differentiated, fusion-negative rhabdomyosarcoma tumor samples, and 8 non-matched normal skeletal muscle samples weer sequenced. BAM files are available for download. Illumina HiSeq 2500;ILLUMINA 22
EGAD00001003745 Exome sequencing fastq files from 6 mutation carriers and 5 non-carriers from 2 families. One µg DNA was used for library preparation using the TruSeq DNA LT Sample Prep Kit v2 according to the manufacturer’s instructions (Illumina). Hybridization was performed using Nimblegen SeqCap EZ Exome v3 (Roche) and Paired-end Sequencing (2x100 bp) on the Illumina HiSeq 2000 with TruSeq v3 chemistry (Illumina). Illumina HiSeq 2000;ILLUMINA 11
EGAD00001003744 Genome and transcriptome sequence data from a pleomorphic xanthoastrocytoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003743 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003742 Genome and transcriptome sequence data from an adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003741 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003740 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003739 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003738 Genome and transcriptome sequence data from a Ewing sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003737 Genome and transcriptome sequence data from a sinus adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003736 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003735 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003734 Genome and transcriptome sequence data from a spindle cell carcinoma of the left parotid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003733 Genome and transcriptome sequence data from a metastatic uterine leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003732 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003731 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003730 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003729 Genome and transcriptome sequence data from a peripheral T-cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003728 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003727 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003726 Genome and transcriptome sequence data from a large-cell neuroendocrine lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003725 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectosigmoid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003724 Genome and transcriptome sequence data from a T-cell rich B cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003723 Genome and transcriptome sequence data from a squamous cell carcinoma of the anus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003722 Genome and transcriptome sequence data from a primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003721 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003720 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003719 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003718 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003717 Genome and transcriptome sequence data from a metastatic non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003716 Genome and transcriptome sequence data from a melanoma of the right buccal mucosa patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003715 Genome and transcriptome sequence data from a metastatic cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003714 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003713 Genome and transcriptome sequence data from a low-grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003712 Genome and transcriptome sequence data from a primary of unknown origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003711 Genome and transcriptome sequence data from a bilateral breast lobular cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003710 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003709 Genome and transcriptome sequence data from a high-grade serous fallopian tube carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003708 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003706 This dataset contains fastq files with Whole genome sequencing data for the CPC-Gene Project. Data from each sample was generated using multiple whole genome libraries and sequenced across multiple runs Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA, unspecified;ILLUMINA 616
EGAD00001003705 10 single-cell placental RNA libraries were generated using the Chromium Single Cell 3′ Reagent Kit (10X Genomics). All single-cell libraries were sequenced with a customized paired end with dual indexing (98/14/8/10-bp) format according to the recommendation by 10X Genomics. The data were aligned using the Cell Ranger Single-Cell Software Suite (version 1.0). Moreover, plasma RNA from 22 samples were extracted using the RNeasy Mini Kit (Qiagen). cDNA reverse transcription, second-strand synthesis, and RNA-sequencing (RNA-seq) library construction were performed using the Ovation RNA-seq System V2 (NuGEN) kit according to the manufacturer’s protocol. For alignment of the plasma RNA library, adaptor sequences and low-quality bases on the fragment ends (i.e., quality score < 5) were trimmed, and reads were aligned to the human reference genome (hg19) using the TopHat (v2.0.4) software. All aligned reads were deposited in bam file format. Illumina HiSeq 2000;ILLUMINA, NextSeq 500;ILLUMINA 32
EGAD00001003702 Genome and transcriptome sequence data from a high grade serous carcinoma of the fallopian tube/ovary/peritoneum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003701 Genome and transcriptome sequence data from a metastatic myoepithelial carcinoma of parotid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003700 Genome and transcriptome sequence data from a thymic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003699 Genome and transcriptome sequence data from a metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003698 Genome and transcriptome sequence data from a locally advanced right breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003697 Genome and transcriptome sequence data from a metastatic meningioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003696 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003695 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003694 Genome and transcriptome sequence data from a pleomorphic sarcomatoid epithelioid carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003693 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003692 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumour patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003691 Genome sequence data from a metastatic squamous cell carcinoma of the oropharynx patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003690 Transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 1
EGAD00001003689 Genome and transcriptome sequence data from a metastatic epitheloid angiomyelolipoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003688 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003687 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003686 Genome and transcriptome sequence data from a metastatic neuroendocrine tumor arising from small bowel patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003685 Genome and transcriptome sequence data from an osterosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003684 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003683 Genome and transcriptome sequence data from a metastatic high grade sarcomatous neoplasm nos patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003682 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003681 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003680 Genome and transcriptome sequence data from a low grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003679 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003678 Genome and transcriptome sequence data from a thymoma carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003677 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003676 Genome and transcriptome sequence data from a metastatic adrenocortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003675 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003674 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003673 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the ge junction patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003672 Genome and transcriptome sequence data from a metastatic clear cell ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003671 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003670 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003669 Genome and transcriptome sequence data from a metastatic mucinous adenocarcinoma of the rectum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003668 Genome and transcriptome sequence data from a metastatic rhabdomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003667 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003666 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003665 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003664 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003663 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003662 Genome and transcriptome sequence data from a left cavernous sinus invasive skull meningioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003661 Genome and transcriptome sequence data from an advanced adenocarcinoma of lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003660 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003659 Genome and transcriptome sequence data from an ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003658 Genome and transcriptome sequence data from a primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003657 Genome and transcriptome sequence data from an adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003656 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003655 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003654 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003653 Genome and transcriptome sequence data from a non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003652 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003651 Genome and transcriptome sequence data from a metastatic colon adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003650 Genome and transcriptome sequence data from a metastatic non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003649 Genome and transcriptome sequence data from a metastatic colon adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003648 Genome and transcriptome sequence data from a glioblastoma multiforme patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003647 Genome and transcriptome sequence data from an anal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003646 Genome and transcriptome sequence data from a squamous cell carcinoma of ge junction patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003645 Genome and transcriptome sequence data from an anaplastic ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003644 Genome and transcriptome sequence data from a metastatic spindle cell sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003643 Genome and transcriptome sequence data from a metastatic cecal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003642 Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003641 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003640 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003639 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003638 Genome and transcriptome sequence data from a metastatic prostate cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003637 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003636 Genome and transcriptome sequence data from a metastatic paraganglioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003635 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003634 Genome and transcriptome sequence data from a solitary fibrous tumors (sarcoma) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003633 Genome and transcriptome sequence data from a metastatic rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003632 Genome and transcriptome sequence data from a chronic lymphocytic leukemia patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003631 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003630 Genome and transcriptome sequence data from a radiation-induced pleomorphic sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003629 Genome and transcriptome sequence data from a metastatic gastric cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003628 Genome and transcriptome sequence data from a metastatic adenocarcinoma of appendiceal origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003627 Genome and transcriptome sequence data from a salivary duct carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003626 Genome and transcriptome sequence data from a retroperitoneal mucinous cystic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003625 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003624 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003623 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003622 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003621 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003620 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003619 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003618 Genome and transcriptome sequence data from a mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003617 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003616 Genome and transcriptome sequence data from an adenocarcimona of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003615 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003614 Genome and transcriptome sequence data from a metastatic non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003613 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003612 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003611 Genome and transcriptome sequence data from a metastatic cecal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003610 Genome and transcriptome sequence data from a mullerian mixed tumor with carcinosarcoma of the ovaries patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003609 Genome and transcriptome sequence data from a metastatic serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003608 Genome and transcriptome sequence data from a metastatic small cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003607 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003606 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003605 Genome and transcriptome sequence data from a metastatic colonic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003604 Genome and transcriptome sequence data from a metastatic gallbladder cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003603 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003602 Dataset consisting of: (1) N=234 genome-wide chromatin accessibility (ATAC-seq) profiles for distinct N=21 healthy old and N=28 healthy young subjects. ATAC-seq biological samples provided for the following tissues: PBMC (N=24), CD14+ monocytes (N=18), CD8+ memory T cells (N=7), CD8+ naive T cells (N=7), CD4+ memory T cells (N=7), CD4+ naive T cells (N=7), and naive B cells (N=7). (2) N=39 genome-wide transcription (RNA-seq) data for distinct N=15 healthy old and N=24 healthy young subjects' PBMCs. Illumina HiSeq 2500;ILLUMINA 273
EGAD00001003601 The dataset for Direct Detection of Early-Stage Cancers using Circulating Tumor DNA includes 602 bam files from next-generation sequencing on the Illumina HiSeq2500 or MiSeq. The samples analyzed include cancer cell lines as well as plasma and tissue specimens from healthy individuals and patients with cancer. Illumina MiSeq;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 550
EGAD00001003600 Exome sequencing data for 1001 DLBCL patients and RNA sequencing data for 775 DLBCL patients Illumina HiSeq 2500;ILLUMINA 1,776
EGAD00001003597 Promoter capture HiC on KMS11 (multiple myeloma) Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003596 The MITOEXME project aims to improve protocols for molecular diagnosis of patients with OXPHOS disorders with a focus on a next generation sequencing methods and to increase the knowledge of pahtophysiological mechanisms by identification of new targets and cellular studies. In this project we will sequence the exomes fo 120 patients. This dataset contains all the data available for this study on 2017-08-29. Illumina HiSeq 2000;ILLUMINA 125
EGAD00001003594 This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ This dataset contains all the data available for this study on 2017-08-29. Illumina HiSeq 2500;ILLUMINA, Illumina HiSeq 4000;ILLUMINA 391
EGAD00001003593 Complete Genomics;COMPLETE_GENOMICS 24
EGAD00001003592 Merged bam files for PACA-CA Whole Exome Sequencing, for DCC release 25 216
EGAD00001003591 Merged bam files for PACA-CA Whole Genome Sequencing, for DCC release 25 211
EGAD00001003590 Ultra-Fast Patient-Derived Xenografts Identify Functional and Spatial Tumour Heterogeneities that Drive Therapeutic Resistance - WXS unaligned reads Illumina HiSeq 2500;ILLUMINA 27
EGAD00001003589 Ultra-Fast Patient-Derived Xenografts Identify Functional and Spatial Tumour Heterogeneities that Drive Therapeutic Resistance - WXS mapped reads 27
EGAD00001003586 Whole Genomes Define Concordance in Matched Primary, Xenograft, and Organoid Models of Pancreas Cancer - WGS mapped reads 54
EGAD00001003585 Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial - WGS mapped reads 106
EGAD00001003584 Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial - RNA-Seq mapped reads 50
EGAD00001003583 516 DNA samples were collected from individuals upon enrollment into the European Prospective Investigation into Cancer and Nutrition study between 1993 and 1998 across 17 different centers. 126bp pair-end reads sequencing data from the Illumina platform were converted to fastq format, the 2bp molecular barcode information at each read of the pair was trimmed and was written in the reads name. The Thymine nucleotide required for ligation was removed from the sequences. Burroughs-Wheeler Aligner (BWA-mem) was used for alignment of the processed fastq files to the reference hg19 genome, following indel-re-alignment using GATK. An in-house algorithm was written to collapse read families that share the same molecular barcode sequence 516
EGAD00001003582 Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial - RNA-Seq unmapped reads Illumina HiSeq 2500;ILLUMINA 50
EGAD00001003580 WGS sequencing for 310 tumor normal pairs from ICGC ESAD-UK project Tumors 50x Normals 30x HiSeq X bam files These samples are all available in ICGC release 26 Illumina HiSeq 2000 (ILLUMINA) 620
EGAD00001003579 Samples prepared using Safe-SeqS technology. All samples ran on an Illumina MiSeq instrument. Fastq files for read 1 and the index read present (R and I respectively). Illumina MiSeq;ILLUMINA 49
EGAD00001003565 The project is focused on the axonal forms of Charcot-Marie-Tooth (CMT) disease. We have selected 13 families (7 from Spain and 6 from Czech Republic) that have been indepth clinically assessed and previously tested for mutations in known CMT genes without causal variants characterised. In these patients we expect to discover several CMT2 genes. Thus, we requested for exome sequencing of 45 DNAs:27 exomes in families from Spain and 18 exomes in the families from Czech Republic. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ This dataset contains all the data available for this study on 2017-08-16. Illumina HiSeq 2500;ILLUMINA 45
EGAD00001003564 The aim of the project is the definition of the molecular defect in a cohort of Rett-like patients negative for mutations in known disease genes. To this aim, a number of unrelated trios (patients plus parents) will be analysed by exome sequencing. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ This dataset contains all the data available for this study on 2017-08-16. Illumina HiSeq 2500;ILLUMINA 46
EGAD00001003563 Whole exome sequencing of diffuse intrinsic pontine glioma (DIPG) cells isolated from the pons and from a sub-ventricular zone site of spread within the frontal lobe from the same individual (SU- DIPG-XIII) Illumina HiSeq 2000;ILLUMINA 3 sample
EGAD00001003562 This dataset includes bam files from 120 samples. These samples were sequenced using 2x150bp reads on an Illumina HiSeqX sequencer and aligned using the Isaac aligner. All samples were processed with TruSeq DNA PCR-free sample preparation. HiSeq X Ten;ILLUMINA 120
EGAD00001003561 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: MALY-DE. 99
EGAD00001003560 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: MALY-DE. 99
EGAD00001003559 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: RECA-EU. 100
EGAD00001003558 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: RECA-EU. 100
EGAD00001003556 We will perform RNAseq to evaluate the effects of the loss of a list of TSGs on the transcriptome. This dataset contains all the data available for this study on 2017-08-10. Illumina HiSeq 2500;ILLUMINA 25
EGAD00001003551 The samples include paired tumor and normal tissues from 106 patients . High-coverage WES sequencing or whole genome sequencing of DNA samples were performed on the Illumina HiSeq 2000 system Illumina HiSeq 2000;ILLUMINA 212
EGAD00001003550 Cell line exome sequencing Illumina HiSeq 2500;ILLUMINA 176
EGAD00001003549 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: CLLE-ES. 74
EGAD00001003548 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: CLLE-ES. 74
EGAD00001003547 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: LIRI-JP. 130
EGAD00001003546 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: LIRI-JP. 130
EGAD00001003543 HipSci - Usher Syndrome - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 27
EGAD00001003542 HipSci - Retinitis Pigmentosa - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 2
EGAD00001003541 HipSci - Macular Dystrophy - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 3
EGAD00001003540 HipSci - Hypertrophic Cardiomyopathy - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 18
EGAD00001003539 HipSci - Bleeding and Platelet Disorders - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 7
EGAD00001003538 HipSci - Hereditary Cerebellar Ataxias - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 11
EGAD00001003537 HipSci - Hereditary Spastic Paraplegia - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 6
EGAD00001003536 HipSci - Primary Immune Deficiency - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 8
EGAD00001003535 HipSci - Kabuki Syndrome - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 6
EGAD00001003534 HipSci - Congenital Hyperinsulinia - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 5
EGAD00001003532 HipSci - Alport Syndrome - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 7
EGAD00001003531 HipSci - Bardet-Biedl Syndrome - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 59
EGAD00001003530 HipSci - Monogenic Diabetes - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 43
EGAD00001003529 HipSci - Healthy Normals - RNA Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 193
EGAD00001003528 HipSci - Usher Syndrome - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA), Illumina HiSeq 2500;ILLUMINA 27
EGAD00001003527 HipSci - Retinitis Pigmentosa - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 2
EGAD00001003526 HipSci - Primary Immune Deficiency - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 8
EGAD00001003525 HipSci - Macular Dystrophy - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 3
EGAD00001003524 HipSci - Kabuki Syndrome - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 6
EGAD00001003523 HipSci - Hypertrophic Cardiomyopathy - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA), Illumina HiSeq 2500;ILLUMINA 18
EGAD00001003522 HipSci - Hereditary Spastic Paraplegia - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 6
EGAD00001003521 HipSci - Hereditary Cerebellar Ataxias - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 11
EGAD00001003520 HipSci - Congenital Hyperinsulinia - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 5
EGAD00001003519 HipSci - Bleeding and Platelet Disorders - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 7
EGAD00001003518 HipSci - Battens Disease - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 4
EGAD00001003517 HipSci - Alport Syndrome - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 7
EGAD00001003516 HipSci - Monogenic Diabetes - Exome Sequencing - July 2017 Illumina HiSeq 2500 (ILLUMINA) 43
EGAD00001003513 This dataset includes bam files from 3,001 samples. These bam files include all read pairs where at least one of the reads aligns within 1kb of the C9orf72 repeat expansion. Additionally, these bam files also contain reads that are aligned to any of 29 pre-determined off target locations where the aligners are known to mis-align reads associated with this repeat expansion. These samples were sequenced using a combination of 2x100bp reads on an Illumina HiSeq2000 and 2x150bp reads on an Illumina HiSeqX sequencer and aligned using the Isaac aligner. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2000;ILLUMINA 3,001
EGAD00001003512 This dataset includes bam files from 58 samples. These bam files include all read pairs where at least one of the reads aligns within 1kb of the HTT repeat expansion. These samples were sequenced using 2x150bp reads on an Illumina HiSeqX sequencer and aligned using bwa. Twelve of the samples used TruSeq Nano library preparation and 46 samples used TruSeq DNA PCR-free sample preparation. HiSeq X Ten;ILLUMINA 58
EGAD00001003511 BAM files with sequencing reads derived from Oxford Nanopore MinION whole genome sequencing of two DNA samples from lymphoblastoid cell lines from two patients with congenital disease. Samples were prepared using 1D and 2D library preps. MinION;OXFORD_NANOPORE 2
EGAD00001003510 BAM files with sequencing reads derived from Illumina whole genome sequencing of two DNA samples from lymphoblastoid cell lines from two patients with congenital disease. Whole genome sequencing was performed using Illumina HiSeq X Ten and samples were prepared using TruSeq library prep. HiSeq X Ten;ILLUMINA 2
EGAD00001003509 Whole Exome Sequencing reads consisting of BAM paired end reads from Follicular Lymphoma samples. 11
EGAD00001003506 A IPS06_X_ENeuron_smRNA-Seq single end data for Early neuron cells(Tuj1) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003505 A IPS05_X_NPC_smRNA-Seq single end data for Neural progenitor cells(Nestin) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003504 A IPS04_X_Fibroblast_smRNA-Seq single end data for iPSC(Oct4) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003503 A IPS03_N_ENeuron_smRNA-Seq single end data for Early neuron cells(Tuj1) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003502 A IPS02_N_NPC_smRNA-Seq single end data for Neural progenitor cells(Nestin) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003501 A IPS01_N_Fibroblast_smRNA-Seq single end data for iPSC(Oct4) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003500 A CKD27_C_Mesan_smRNA-Seq single end data for Mesangial cells(kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003499 A CKD25_C_Podo_smRNA-Seq single end data for Podocytes(CD90(-) Podocalyxin(+), kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003498 A CKD24_C_Podo_smRNA-Seq single end data for Podocytes(CD90(-) Podocalyxin(+), kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003497 A CKD23_C_Mesan_smRNA-Seq single end data for Mesangial cells(kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003496 A OB57_D_PreA_smRNA-Seq single end data for Preadipocyte(fat) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003495 A OB56_N_PreA_smRNA-Seq single end data for Preadipocytes(fat) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003494 A DB31_N_Alpha_smRNA-Seq single end data for alpha cells(PSA-NCAM(-), pancreas) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003493 A IPS06_X_ENeuron_mRNA-Seq paired end data for Early neuron cells(Tuj1) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003492 A IPS05_X_NPC_mRNA-Seq paired end data for Neural progenitor cells(Nestin) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003491 A IPS04_X_Fibroblast_mRNA-Seq paired end data for iPSC(Oct4) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003490 A IPS03_N_ENeuron_mRNA-Seq paired end data for Early neuron cells(Tuj1) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003489 A IPS02_N_NPC_mRNA-Seq paired end data for Neural progenitor cells(Nestin) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003488 A IPS01_N_Fibroblast_mRNA-Seq paired end data for iPSC(Oct4) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003487 A OB57_D_PreA_mRNA-Seq paired end data for Preadipocyte(fat) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003486 A OB56_N_PreA_mRNA-Seq paired end data for Preadipocytes(fat) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003485 A DB31_N_Alpha_mRNA-Seq paired end data for alpha cells(PSA-NCAM(-), pancreas) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003484 A CKD27_C_Mesan_mRNA-Seq paired end data for Mesangial cells(kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003483 A CKD25_C_Podo_mRNA-Seq paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003482 A CKD24_C_Podo_mRNA-Seq paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003481 A CKD23_C_Mesan_mRNA-Seq paired end data for Mesangial cells(kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003480 A OB57_D_PreA_WGBS paired end data for Preadipocyte(fat) HiSeq X Ten;ILLUMINA 1
EGAD00001003479 A OB56_N_PreA_WGBS paired end data for Preadipocytes(fat) HiSeq X Ten;ILLUMINA 1
EGAD00001003478 A IPS06_X_ENeuron_WGBS paired end data for Early neuron cells(Tuj1) HiSeq X Ten;ILLUMINA 1
EGAD00001003477 A IPS05_X_NPC_WGBS paired end data for Neural progenitor cells(Nestin) HiSeq X Ten;ILLUMINA 1
EGAD00001003476 A IPS04_X_Fibroblast_WGBS paired end data for iPSC(Oct4) HiSeq X Ten;ILLUMINA 1
EGAD00001003475 A IPS03_N_ENeuron_WGBS paired end data for Early neuron cells(Tuj1) HiSeq X Ten;ILLUMINA 1
EGAD00001003474 A IPS02_N_NPC_WGBS paired end data for Neural progenitor cells(Nestin) HiSeq X Ten;ILLUMINA 1
EGAD00001003473 A IPS01_N_Fibroblast_WGBS paired end data for iPSC(Oct4) HiSeq X Ten;ILLUMINA 1
EGAD00001003472 A DB31_N_Alpha_WGBS paired end data for alpha cells(PSA-NCAM(-), pancreas) HiSeq X Ten;ILLUMINA 1
EGAD00001003471 A CKD27_C_Mesan_WGBS paired end data for Mesangial cells(kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003470 A CKD25_C_Podo_WGBS paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003469 A CKD24_C_Podo_WGBS paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003468 A CKD23_C_Mesan_WGBS paired end data for Mesangial cells(kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003467 This dataset contains 77 tumor-normal pairs of exome sequencing data of HCC patient from National Taiwan University, Taiwan. Illumina HiSeq 2500;ILLUMINA 154
EGAD00001003466 This dataset contains 21 tumor-normal pairs of exome sequencing data of HCC patient from Chang Gung Memorial Hospital, Taiwan. Illumina HiSeq 2500;ILLUMINA 42
EGAD00001003464 For RNA-Seq total RNA was isolated following LDC67 or JQ1 treatment. 3’RNAseq libraries were prepared with QUANT SEQ FWD 3´mRNA-Seq Kit (Lexogen, Austria), sequenced on an Illumina HiSeq 4000 Illumina HiSeq 2000;ILLUMINA 3
EGAD00001003463 These are the vcf files of exome sequencing of the two probands who were found to harbor mutations in KLB. Sample: EGAN00001564799 is the proband 1; Sample: EGAN00001564800 is the proband 11 in the KLB paper. Exome capture was performed using the SureSelect All Exon capture (Agilent Technologies, Santa Clara, CA USA) and sequenced on the HiSeq2500 (Illumina, San Diego CA USA). 2
EGAD00001003461 H3K27ac ChIP-seq and input genome sequencing was performed in 19 primary prostate tumours classified as intermediate risk. Sequencing of ChIP DNA was performed on an Illumina HiSeq 2000 as either single end 50 bp reads (for 7 samples) or paired end 100 bp reads (for 12 samples). Input DNA from all samples was sequenced using single-end 50 bp reads. The files provided are in fastq format. Illumina HiSeq 2000;ILLUMINA 27
EGAD00001003458 Fastq data of genomics heterogeneity of multiple synchronous lung cancer. Whole-genome sequencing (WGS) were performed in 3 tumour samples, one regional lymph node metastasis sample and peripheral blood sample from the same patient with MSLCs. Illumina HiSeq 2000;ILLUMINA 6
EGAD00001003456 There are 5WGS and 35WES sample pairs from the first affiliated hospital of kunming medical university, which belongs to ICGC projects COCA-CN. Illumina HiSeq 2000;ILLUMINA 80
EGAD00001003455 The MHC vcf call set was generated using a modified AsmVar and BayesTyper pipeline. In contrast to the original pipeline, where variant calling is performed using alignment of collapsed assemblies to a reference genome, the MHC call set was produced using alignment of phased MHC haplotypes. Two iterations of BayesTyper was run, a first iteration for each haplotype seperately and a second iteration performing joint variant calling on all haplotypes. The sample IDs for the fathers and mothers are TrioID-01 and TrioID-02, respectively, and the IDs for the children are TrioID-0x, where x is a number between 3 and 7. 25
EGAD00001003454 Validation of HLA variation of 8 individuals from the GenomeDenmark Phase 2 study. Validation is performed Sanger sequencing of selected amplicons (5-10 amplicons per sample). AB 3730xL Genetic Analyzer;CAPILLARY 8
EGAD00001003453 16S sequencing of stool samples of LifeLines-DEEP, domain V4 Illumina MiSeq;ILLUMINA 1,010
EGAD00001003452 The samples include paired tumor and normal tissues from 205 patients (201 for normal and primary tumor tissues; 4 for normal, primary tumor and liver metastatic tissues). High-coverage WES sequencing or whole genome sequencing of DNA samples were performed on the Illumina HiSeq 2000 system Illumina HiSeq 2000;ILLUMINA 30
EGAD00001003448 strand-specific RNA-seq data from 19 gastric tumors and their adjacent normal tissues, plus 16 gastric cancer cell lines, one normal gastric cell line, and 3 normal stomach RNAs Illumina HiSeq 2500;ILLUMINA 58
EGAD00001003446 This dataset includes deep coverage (>60x) whole exomes of 15 human embryonic stem cell lines. Genomic DNA was purified and fragmented using the Illumina Nextera system for library preparation and sequenced using 150bp paired-end reads. Sequencing reads were aligned to the hg19 reference genome using the BWA MEM alignment program. HiSeq X Ten;ILLUMINA 15
EGAD00001003445 Clear cell renal cancer is characterized by near-universal loss of the short arm of chromosome 3 (3p). This event arises through unknown mechanisms, but critically results in the loss of several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with clear cell renal cancer (ccRCC) recruited into the Renal TRACERx study. We find novel hotspots of point mutations in the 5'-UTR of TERT, targeting a MYC-MAX repressor, that result in telomere lengthening. The most common structural abnormality generates simultaneous 3p loss and 5q gain (36% patients), typically through chromothripsis. Using molecular clocks, we estimate this occurs in childhood or adolescence, generally preceding emergence of the most recent common ancestor by years to decades. Similar genomic changes recent common ancestor by years to decades. Similar genomic changes are seen in inherited kidney cancers. Modeling differences in age-incidence between inherited and sporadic cancers suggests that the number of cells with 3p loss capable of initiating sporadic tumors is no more than a few hundred. Targeting essential genes in deleted regions of chromosome 3p could represent a potential preventative strategy for renal cancer. HiSeq X Ten;ILLUMINA 164
EGAD00001003443 Massively parallel nanowell-based single-cell gene expression profiling Illumina HiSeq 2500;ILLUMINA 14
EGAD00001003440 One file of patient 16 with WGS done on Illumina HiSeq X-Ten. For research purpose and authorised user only. HiSeq X Ten;ILLUMINA 1
EGAD00001003439 Three files of patients 10, 11 and 13 with WGS done on Illumina HiSeq X Ten. For research purpose and authorised user only. HiSeq X Ten;ILLUMINA 3
EGAD00001003438 Three files of patients 20, 23 and 25 with WGS done on Illumina HiSeq 2000. For research purpose and authorised user only. Illumina HiSeq 2000;ILLUMINA 3
EGAD00001003437 Fourteen files of patients 1, 2, 4, 6, 7, 8, 9, 12, 14, 16, 17, 18, 19 and 27 with WGS done on Illumina MiSeq with low coverage. For research purpose and authorised user only. Illumina MiSeq;ILLUMINA 14
EGAD00001003436 Seven files of patients 3, 21, 29, 30, 31, 32 and 33 with WGS done on Illumina MiSeq with high coverage. For research purpose and authorised user only. Illumina MiSeq;ILLUMINA 7
EGAD00001003435 Whole Genome Sequencing for the paper titled "Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors" Illumina HiSeq 2000;ILLUMINA 150
EGAD00001003434 Whole Exome Sequencing for the paper titled "Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors" Illumina HiSeq 2000;ILLUMINA 149
EGAD00001003433 RNA-Seq data for the paper titled "Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors" Illumina HiSeq 2000;ILLUMINA 95
EGAD00001003432 ChIP-Seq data for the paper titled "Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors" Illumina HiSeq 2000;ILLUMINA 20
EGAD00001003431 High-coverage WGS sequencing of DNA samples from 45pairs GCs was performed on the Illumina HiSeq X Ten System. Illumina HiSeq 2000 (ILLUMINA) 88
EGAD00001003430 RNA analysis of six patients 34, 35, 36, 37, 38 and 39 with WGS done on Illumina HiSeq2500. For research purpose and authorised user only. Illumina HiSeq 2500;ILLUMINA 6
EGAD00001003429 RNA analysis of two patients 11 and 15 with WGS done on Illumina HiSeq2000. For research purpose and authorised user only. Illumina HiSeq 2000;ILLUMINA 2
EGAD00001003428 RNAseq data from the study: "Widespread DNA hypomethylation and differential gene expression in Turner syndrome". Illumina HiSeq 2000;ILLUMINA, NextSeq 500;ILLUMINA 37
EGAD00001003425 A EGFR mutant NSCLC cell line which is sensitive to AZD9291 inhibition was mutagenised with the chemical mutagen ENU and then drug selected using a AZD9291. Single cell derived colonies were then manually picked and expanded in drug. Resistance was confirmed in a 14 day assay and DNA was collected. These then underwent targeted amplicon-based sequencing to confirm candidate resistance effectors hypothesised from currently available literature. This dataset contains all the data available for this study on 2017-07-05. Illumina MiSeq;ILLUMINA 177
EGAD00001003422 WXS from barcoded cells that are FACS sorted from GBM-719 xenografts, and the germline reference from patient GBM-719. The 4 xenografts are named according to passage (secondary or tertiary) and treatment (vehicle control or temozolomide). Illumina HiSeq 2500;ILLUMINA 5
EGAD00001003421 Sequence data of 28 Samples (19 chronic lymphocytic leukemia, 9 control) Including RNA-Seq and ChIP-Seq of following histone modifications: H3, H3K4me1, H3K4me3, H3K9ac, H3K9me3, H3K27ac, H3K27me3, H3K36me3 Project see: http://www.cancerepisys.org/ 28
EGAD00001003419 Illumina HiSeq 2000;ILLUMINA 50
EGAD00001003416 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: OV-AU. 93
EGAD00001003415 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: OV-AU. 93
EGAD00001003414 June 2017 data update (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500;ILLUMINA, NextSeq 500;ILLUMINA 40
EGAD00001003411 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: PACA-AU. 81
EGAD00001003410 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: PACA-AU. 81
EGAD00001003409 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are part of a clinical, pathological and genetic continuum. The purpose of the present study was to assess the mutation burden that is present in ALS and/or FTD known disease-causing genes in 54 patients (16 with available postmortem neuropathological diagnosis) with concurrent ALS and FTD (ALS/FTD) not-carrying the C9orf72 hexanucleotide repeat expansion, the most important genetic cause in both diseases. Illumina HiSeq 2500;ILLUMINA 54
EGAD00001003407 Whole-genome sequencing and phasing of admixed Aboriginal Australian genomes and Papua New Guinean genomes using 10x Genomics Chromium technology. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/ This dataset contains all the data available for this study on 2017-06-27. HiSeq X Ten;ILLUMINA 4
EGAD00001003405 High-coverage WGS sequencing of DNA samples from 23pairs GCs was performed on the Illumina HiSeq X Ten System. Illumina HiSeq 2000;ILLUMINA 46
EGAD00001003400 We present targeted NGS panel data from 170 samples that were processed using the TruSightTM Cancer (TSC) panel (Illumina, San Diego, CA, USA), which targets 94 genes and 284 SNPs associated with a predisposition towards cancer. The samples are enriched for CNVs in the genes of interest. All CNVs have previously been assessed with MLPA and can therefore be considered as confirmed. Illumina MiSeq;ILLUMINA 170
EGAD00001003399 RNAseq dataset of 34 samples (6 normals, 7 stroma-enriched, 21 malignant cells-enriched) from patients with resected pancreatic ductal carcinoma. Illumina HiSeq 4000;ILLUMINA 34
EGAD00001003394 This dataset contains bam files for ChIP-seq experiments for 6 neuroblastoma PDXs (Patient Derived Xenograft). It includes the bam files for the H3K27ac mark as well as the bam files of the corresponding input DNA for each sample. Illumina HiSeq 2500 (ILLUMINA) 6
EGAD00001003393 This dataset contains bam files for RNA-seq experiments for 6 neuroblastoma PDXs (Patient Derived Xenograft) and 3 pairs of neuroblastoma tumors at diagnosis and at relapse. NextSeq 500 (ILLUMINA), Illumina HiSeq 2500 (ILLUMINA), Illumina HiSeq 4000 (ILLUMINA) 12
EGAD00001003392 High-coverage WGS sequencing of DNA samples from 51pairs GCs was performed on the Illumina HiSeq X Ten System. Illumina HiSeq 2000;ILLUMINA 102
EGAD00001003391 DCM-controls (113 human non-DCM samples) human heart biopsies from 113 non-diseased controls were subjected to RNA sequencing in order to assess transcriptome variation. We used Illumina HiSeq2000 technology. Each sample-dataset contains the output from tophat-1.4.1 (one *.bam file with the aligned reads and two *.fq files one with the not aligned forward read and one with the revers unaligned reads). We reveal extensive differences of gene expression and splicing between dilated cardiomyopathy patients and controls. Illumina HiSeq 2000;ILLUMINA 113
EGAD00001003390 DCM-cases (149 human DCM samples) human heart biopsies from 149 patients with dilated cardiomyopathy (DCM) were subjected to RNA sequencing in order to assess transcriptome variation. We used Illumina HiSeq2000 technology. Each sample-dataset contains the output from tophat-1.4.1 (one *.bam file with the aligned reads and two *.fq files one with the not aligned forward read and one with the revers unaligned reads). We reveal extensive differences of gene expression and splicing between dilated cardiomyopathy patients and controls. Illumina HiSeq 2000;ILLUMINA 149
EGAD00001003388 Aligned, merged and deduplicated BAM files from HiSeq whole genome sequencing of 366 samples: matched tumour-normal pairs from 183 melanoma patients. 366
EGAD00001003387 MinION;OXFORD_NANOPORE 19
EGAD00001003386 Whole-exome sequencing on AB 5500xl Genetic Analyzer of colorectal cancer primary tumor sample (OT2_cohort) AB 5500 Genetic Analyzer;ABI_SOLID 1
EGAD00001003385 Whole-exome sequencing on AB 5500xl Genetic Analyzer of Blood EDTA (OT2_cohort) AB 5500 Genetic Analyzer;ABI_SOLID 1
EGAD00001003384 Whole-exome sequencing on Illumina HiSeq2000/2500 of Patient-derived xenograft derived from colorectal cancer primary tumor sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 14
EGAD00001003383 Whole-exome sequencing on Illumina HiSeq2000/2500 of colorectal cancer primary tumor sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 7
EGAD00001003382 MinION;OXFORD_NANOPORE 26
EGAD00001003381 Whole-exome sequencing on Illumina HiSeq2000/2500 of Patient-derived xenograft derived from colorectal cancer metastasis sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 10
EGAD00001003380 Whole-exome sequencing on Illumina HiSeq2000/2500 of PDO culture derived from colorectal cancer metastasis sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003379 Whole-exome sequencing on Illumina HiSeq2000/2500 of colorectal cancer metastasis sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 4
EGAD00001003378 Whole-exome sequencing on Illumina HiSeq2000/2500 of normal colon control tissue (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003377 Whole-exome sequencing on Illumina HiSeq2000/2500 of Blood EDTA (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 10
EGAD00001003376 Whole-genome sequencing on Illumina HiSeq2000/2500 of Patient-derived xenograft derived from colorectal cancer primary tumor sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 12
EGAD00001003375 Whole-genome sequencing on Illumina HiSeq2000/2500 of colorectal cancer primary tumor sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 7
EGAD00001003374 Whole-genome sequencing on Illumina HiSeq2000/2500 of Patient-derived xenograft derived from colorectal cancer metastasis sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 8
EGAD00001003373 Whole-genome sequencing on Illumina HiSeq2000/2500 of PDO culture derived from colorectal cancer metastasis sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003372 Whole-genome sequencing on Illumina HiSeq2000/2500 of colorectal cancer metastasis sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 4
EGAD00001003371 Whole-genome sequencing on Illumina HiSeq2000/2500 of normal colon control tissue (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003370 Whole-genome sequencing on Illumina HiSeq2000/2500 of Blood EDTA (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 10
EGAD00001003369 RNAseq on Illumina HiSeq2000/2500 of Patient-derived xenograft derived from colorectal cancer primary tumor sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 13
EGAD00001003368 RNAseq on Illumina HiSeq2000/2500 of PDO culture derived from colorectal cancer primary tumor sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003367 RNAseq on Illumina HiSeq2000/2500 of colorectal cancer primary tumor sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 7
EGAD00001003366 RNAseq on Illumina HiSeq2000/2500 of Patient-derived xenograft derived from colorectal cancer metastasis sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 10
EGAD00001003365 RNAseq on Illumina HiSeq2000/2500 of PDO culture derived from colorectal cancer metastasis sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003364 RNAseq on Illumina HiSeq2000/2500 of colorectal cancer metastasis sample (OT2_cohort) Illumina HiSeq 2000;ILLUMINA 4
EGAD00001003363 Whole-exome sequencing on Illumina HiSeq2000/2500 of Patient-derived xenograft derived from colorectal cancer primary tumor sample (EPO2_cohort) Illumina HiSeq 2000;ILLUMINA 114
EGAD00001003362 RNAseq on Illumina HiSeq2000/2500 of Patient-derived xenograft derived from colorectal cancer primary tumor sample (EPO2_cohort) Illumina HiSeq 2000;ILLUMINA 49
EGAD00001003361 VCF files containing mitochondrial variant calls using MToolbox 432
EGAD00001003360 Bam files containing mitochondrial alignments, extracted from CPCGene Whole Genome Alignments 432
EGAD00001003359 In this study, we present the results of a custom “pan-cardiomyopathy panel” in a molecular screening of 38 unrelated patients, 16 affected by DCM, 14 by HCM, and 8 by ARVC. The panel was designed using the Design Studio Tool (Illumina, San Diego, CA,USA). Coding regions and intron–exon boundaries of 115 genes, known to be associated with 7 DCM, HCM, and ARVC as well as channelopathies, were selected for targeted gene enrichment. For genes with multiple transcripts, all exons included in transcripts expressed in cardiac muscle were considered in the gene panel design. Total DNA was extracted from peripheral blood samples using the Wizard Genomic DNA Purification Kit (Promega, Mannheim, Germany) according to the manufacturer’s instructions, quantified, and qualitatively checked using NanoDrop 2000c (Thermo Fisher Scientific, Waltham, MA, USA). Custom targeted gene enrichment and DNA library preparation were performed using the Nextera Capture Custom Enrichment kit (Illumina) according to the manufacturer’s instructions. Targeted regions were sequenced using the Illumina MiSeq platform, generating approximately two millions of 150-bp paired-end reads for each sample (Q30 ≥90%). Illumina MiSeq;ILLUMINA 38
EGAD00001003357 Aligned, merged and deduplicated BAM files from HiSeq whole exome sequencing of 106 samples: matched tumour-normal pairs from 53 melanoma patients. 106
EGAD00001003355 From 17 patients undergoing knee joint replacement surgery for osteoarthritis, we collected 4 samples each: intact cartilage, degraded cartilage, synovium, and meniscus. We also collected blood for DNA analysis. Multiplexed libraries were sequenced on Illumina HiSeq 2000 (75bp paired-end read length) and a cram file was produced for each sample. This dataset contains all the data available for this study on 2017-06-09. Illumina HiSeq 2500;ILLUMINA 72
EGAD00001003354 From 9 patients undergoing hip joint replacement surgery for osteoarthritis, we collected 3 cartilage samples each: a low-grade sample (no obvious evidence of damage or fibrillation); a high-grade sample (damaged and fibrillated cartilage); an osteophytic sample (overlaid bony protrusions mainly around the margins of the articular surface). Multiplexed libraries were sequenced on Illumina HiSeq 2000 (75bp paired-end read length) and a cram file was produced for each sample. This dataset contains all the data available for this study on 2017-06-09. Illumina HiSeq 2500;ILLUMINA 27
EGAD00001003353 BAM outputs from STAR (https://github.com/alexdobin/STAR) analysis of RNASeq sequencing on HiSeq platform of 56 tumour samples from 46 melanoma cases. Gene model = Ensembl version 70 56
EGAD00001003351 In order to comprehensively investigate the genetic relationship between PTC tumors and benign nodules, we totally collected 127 fresh-frozen biopsies samples from 28 patients with concurrent thyroid benign nodule and PTC (n=20) or simple benign nodule (n=8). We carried out whole-exome sequencing on all the 127 biopsies samples and RNA-sequencing in total of 40 samples. Illumina HiSeq 2500;ILLUMINA 127
EGAD00001003349 ChIP-seq data (H3K4Me1, H3K4Me3, H3K27Ac histone modifications) in experimental triplicates on multiple myeloma cell line KMS11 and plasma cell leukaemia cell lines L363 and JJN3. ChIP reactions were performed on a Diagenode SX-8G IP-Star Compact using Diagenode automated Ideal Kit. ChIP libraries were generated using HTP Illumina library preparation kit, and sequenced using Illumina HiSeq 2000 with 100 bp single-ended reads. ChIP-seq files are in BED format. Illumina HiSeq 2000;ILLUMINA 9
EGAD00001003348 The differentiation of distinct multifocal hepatocellular carcinoma (HCC): multicentric disease vs. intrahepatic metastases, in which the management and prognosis varies substantively, remains problematic. We aim to stratify multifocal HCC and identify novel diagnostic and prognostic biomarkers by performing whole genome and transcriptome sequencing, as part of a multi-omics strategy. Illumina HiSeq 2000;ILLUMINA 8
EGAD00001003347 This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ This dataset contains all the data available for this study on 2017-05-24. Illumina HiSeq 2000;ILLUMINA 76
EGAD00001003345 exome sequence data for 57 HIV elite long term non-progressors and rapid progressors. Complete dataset of improved BAMs mapped to hs37d5 and including phenotype information. 57
EGAD00001003344 Transcriptome profiling of 25 prostate tumor samples by RNA-Seq Illumina HiSeq 2000;ILLUMINA 25
EGAD00001003341 Sequence data from fungal infection isolated from neural tissue in ALS patients. Illumina MiSeq;ILLUMINA 34
EGAD00001003339 Whole exome library making will be performed on genomic DNA derived from radiotherapy induced sarcoma samples and matched normal DNA from the same patients. Next Generation sequencing will be performed on the resulting libraries and mapped to build 37 of the human reference genome to facilitate the identification of mutations This dataset contains all the data available for this study on 2017-05-17. Illumina HiSeq 2000;ILLUMINA 7
EGAD00001003337 T cells isolated from peripheral blood, tumors and adjacent normal tissues from six hepatocellular carcinoma patients. SmartSeq2 and Tang2009 protocol were used to amplify RNA from single T cells. High depth enables simultaneously expression profiling and TCR assembling. Illumina HiSeq 2500 (ILLUMINA), Illumina HiSeq 4000 (ILLUMINA) 5,063
EGAD00001003336 BAM outputs from RSEM (https://deweylab.github.io/RSEM/) analysis of RNASeq sequencing on HiSeq platform of tumour samples from 29 pancreatic neuroendocrine cases. 29
EGAD00001003335 A resource for assessment of exon CNV calling methods in targeted NGS data, we here present the ICR96 exon CNV validation series. The dataset includes high-quality sequencing data from a targeted NGS assay (the TruSight Cancer Panel) together with Multiplex Ligation-dependent Probe Amplification (MLPA) results for 96 independent samples. 66 samples contain at least one validated exon CNV and 30 samples have validated negative results for exon CNVs in 26 genes. The dataset includes 46 exon CNVs in BRCA1, BRCA2, TP53, MLH1, MSH2, MSH6, PMS2, EPCAM and PTEN, giving excellent representation of the cancer predisposition genes most frequently tested in clinical practice. Moreover, the validated exon CNVs include 25 single exon CNVs the most difficult exon CNV to detect. Illumina HiSeq 2500;ILLUMINA 96
EGAD00001003334 Targeted exome sequencing of patient derived xenografts from primary colorectal tumours and liver metastases. This dataset contains all the data available for this study on 2017-05-11. Illumina HiSeq 2000;ILLUMINA 573
EGAD00001003332 PCR and MiSeq validation for early embryonic substitution candidates from 400 Breast cancer patients This dataset contains all the data available for this study on 2017-05-11. Illumina MiSeq;ILLUMINA 4
EGAD00001003331 Whole-exome sequencing of a cohort of families (probands and affected/unaffected relatives) suffering from one of two rare thyroid disorders: congenital hypothyroidism (CH) and resistance to thyroid hormone (RTH). This dataset contains all the data available for this study on 2017-05-11. Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 78
EGAD00001003330 The samples will be sequenced for a targeted panel of cancer relevant genes (n ~ 370) and analysed for somatic mutations. This dataset contains all the data available for this study on 2017-05-11. Illumina HiSeq 2000;ILLUMINA 416
EGAD00001003329 The offspring of first cousin marriages have ~6% of their genome autozygous, i.e. homozygous identical by descent, or even more if there was further consanguinity in their ancestry. In the UK there are large populations with very high first cousin marriage rates of 20-50%. Sequencing the exomes of a sample of these individuals has the potential both to support genetic health programmes in these populations, and to provide genetic research information about rare loss of function mutations. This pilot study based on existing cohort samples from the Born In Bradford study will identify homozygous individuals for almost all variants down to an allele frequency around 1%, plus individuals carrying hundreds of new homozygous rare loss-of-function variants, and will support development of community relations and ethics for a wider study currently being designed. The data deposited in the EGA consist of low coverage whole exome sequencing on these samples. This dataset contains all the data available for this study on 2017-05-11. Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 3,188
EGAD00001003328 Clinical and genetic information of an individual with RVOT-VT and a KCNK2 (TREK1) gene mutation obtained after whole exome sequencing. 1
EGAD00001003326 Azoospermia, characterized by the absence of spermatozoa in the ejaculate is a common cause of male infertility with a poorly characterized etiology. Exome sequencing analysis of two azoospermic brothers allowed the identification of a homozygous splice mutation in SPINK2, encoding a serine protease inhibitor believed to target acrosin, the main sperm acrosomal protease. In accord with these findings we observed that homozygous Spink2 KO male mice had azoospermia. Moreover, despite normal fertility, heterozygous male mice had a high rate of morphologically abnormal spermatozoa and a reduced sperm motility. Further analysis demonstrated that in the absence of Spink2, protease-induced stress initiates Golgi fragmentation and prevents acrosome biogenesis leading to spermatid differentiation arrest. We also observed a deleterious effect of acrosin overexpression in HEK cells, effect that was alleviated by SPINK2 coexpression confirming its role as acrosin inhibitor. These results demonstrate that SPINK2 is necessary to neutralize proteases during their cellular transit towards the acrosome and that its deficiency induces a pathological continuum ranging from oligoasthenoteratozoospermia in heterozygotes to azoospermia in homozygotes. Illumina HiSeq 2000;ILLUMINA 2
EGAD00001003321 Systematic next generation sequencing efforts are beginning to define the genomic landscape across a range of primary tumours, but we know very little of the mutational evolution that contributes to disease progression. We therefore propose to obtain a comprehensive description of genomic, transcriptomic and epigenomic changes in a cohort of matched primary and metastatic colorectal cancers, and additionally to explore the extent to which those mutations identified as recurrent in the metastatic setting are able to subvert normal biological processes using both genetically engineered mouse models and established cancer cell lines. This study will enable us to define to what extent primary tumour profiling can capture the biological processes operative in matched metastases as well as the significance of intratumoural heterogeneity. This dataset contains all the data available for this study on 2017-05-04. Illumina HiSeq 2000;ILLUMINA 523
EGAD00001003320 Transcriptome sequencing of tumour tissue, adjacent normal tissue and derived organoids/tumoroids from colorectal cancer This dataset contains all the data available for this study on 2017-05-04. Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 106
EGAD00001003318 RNA-sequencing alignment for SYSCOL colorectal adenoma-carcinoma samples 314
EGAD00001003316 RNAseq of LC2AD with AD80 or DMSO Plenker et al., Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003315 This dataset includes the high-throughput sequencing data from a study entitled "Clonal History and Genetic Predictors of Transformation into Small Cell Carcinomas from Lung Adenocarcinomas". Whole-genome sequencing libraries were generated by PCR-free methods, and sequencing run was made in HiSeq X or HiSeq 2500 machines. PCR duplicates-marked, indel-realigned, and base-recalibrarted BAM files are provided in our dataset. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 15
EGAD00001003311 Dataset contains one sample derived from gDNA of human fibroblasts. Files are in FASTQ format and were generated using the Agilent SureSelect Human All Exon 50Mb Kit and followed by Next Generation Sequencing on a HighSeq2000 instrument (Illumina). Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003310 There are 66 pairs of LAML cases(complete genomics) in this project which belongs to LAML-CN..The library is constructed by the Completes Genomics protocol. Complete Genomics;COMPLETE_GENOMICS 66
EGAD00001003309 The study will investigate serial samples from the same patient taken at the time of MGUS or SMM diagnosis, and later at the time of evolution towards MM. Samples will be sequenced by whole genome along with a matched normal to obtain the highest possible amount of information toinvestigate genomic changes at disease evolution. This dataset contains all the data available for this study on 2017-04-27. HiSeq X Ten;ILLUMINA 139
EGAD00001003308 This is an in vitro genome-wide CRISPR/cas9 screen in human glioblastoma stem cells, screening for genes essential for survival of these cells. These cells express cas9 and have been transfected with a guide RNA library causing gene knockouts. We will analyse the sequencing data for depletion of guide RNAs. This dataset contains all the data available for this study on 2017-04-27. Illumina HiSeq 2000;ILLUMINA 10
EGAD00001003307 In this project we will use exome sequencing to identify somatic mutations in lesions from a patient with a germline mutation in the protection of telomeres 1 gene (POT1). This dataset contains all the data available for this study on 2017-04-27. Illumina MiSeq;ILLUMINA, Illumina HiSeq 2000;ILLUMINA 40
EGAD00001003306 Exome sequencing data of 15 French Caucasian and 10 African-Caribbean men with prostate Cancer. Illumina HiSeq 2000;ILLUMINA 50
EGAD00001003305 Diffuse Intrinsic Pontine Glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children with no effective treatment. To understand what drives DIPGs we integrated whole-genome-sequencing with methylation, expression and copy-number profiling. AB SOLiD System (ABI_SOLID), Illumina HiSeq 2500 (ILLUMINA) 23
EGAD00001003304 We collected tumor samples and adjacent nomal mucosae from 46 patients with colorectal cancer in surgical operation from 2014 to 2016 in the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) and the Research Institute of Surgery, Third Military Medical University (Chongqing, China). the qualified captured library of each sample was then loaded on Illumina HiSeq 2000 (Illumina, San Diego, CA) platforms and subjected to high-throughput sequencing. Complete Genomics;COMPLETE_GENOMICS 38
EGAD00001003303 The evolution of four breast cancers was analyzed using longitudinal samples collected over 2-15 years. Whole-genome sequencing and single-cell RNA-Seq were used to analyze evolution. We have deposited VCF files for SNV, indel, and structural variant calls from WGS data, and a text file showing transcripts per million (TPM) expression for the single-cell RNA-Seq data. 16
EGAD00001003302 Illumina HiSeq 3000;ILLUMINA 21
EGAD00001003301 Whole exome sequencing of 10 metastatic biopsies from four TRACERx100 patients (see EGA dataset EGAS00001002247), collected either after relapse or death. The data from these samples are initially published with Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature, http://dx.doi.org/10.1038/nature22364 (2017). Abstract: Earlier detection of relapse following primary surgery for non-small cell lung cancer and the characterization of emerging subclones seeding metastatic sites might offer new therapeutic approaches to limit tumor recurrence. The potential to non-invasively track tumor evolutionary dynamics in ctDNA of early-stage lung cancer is not established. Here we conduct a patient-specific approach to ctDNA profiling in the first 100 lung TRACERx (TRAcking Cancer Evolution through therapy (Rx)) study participants, including one patient co-recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release in early-stage non-small cell lung cancer and perform tumor volume limit of detection analyses. Through blinded profiling of post-operative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients destined to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastases, providing a new approach for ctDNA driven therapeutic studies. 10
EGAD00001003300 Paired-end reads were aligned to human reference genome build hg19 by BWA. Single nucleotide variants and small insertions/deletions were called by GATK resulting in a single VCF file including all 176 samples. 175
EGAD00001003298 BAM outputs from RSEM (https://deweylab.github.io/RSEM/) analysis of RNASeq sequencing on HiSeq platform of tumour samples from 95 pancreatic adenocarcinoma cases. 96
EGAD00001003297 9
EGAD00001003296 Integrated callset of low coverage Ethiopian and Egyptian genomes from the Pagani et al. 2015 AJHG paper (doi: http://dx.doi.org/10.1016/j.ajhg.2015.04.019) 220
EGAD00001003295 Integrated callset of high coverage Egyptian genomes from the Pagani et al. 2015 AJHG paper (doi: http://dx.doi.org/10.1016/j.ajhg.2015.04.019) 3
EGAD00001003294 Integrated callset of high coverage Ethiopian genomes from the Pagani et al. 2015 AJHG paper (doi: http://dx.doi.org/10.1016/j.ajhg.2015.04.019) 5
EGAD00001003293 RNA-Seq and WXS from 6 glioblastoma patients Illumina HiSeq 2500;ILLUMINA 11
EGAD00001003292 Illumina HiSeq 2000;ILLUMINA 520
EGAD00001003291 This dataset represents RNA-sequencing data from 278 primary colon cancers obtained from fresh-frozen tumor sections. RNA-sequencing was performed using TruSeq library preparation and samples were sequenced on Illumina NextSeq and HiSeq. The data are available as Illumina NextSeq and HiSeq fastq files (_R1.fastq and _R2.fastq for each tumor sample, 556 files in total). NextSeq 500 (ILLUMINA), Illumina HiSeq 2500 (ILLUMINA) 278
EGAD00001003286 Whole genome sequencing data for MMML (7 tumors and 8 controls) 15
EGAD00001003285 RNA sequencing data for MMML (3 tumor samples and 1 gcbcell) 5
EGAD00001003284 Whole exome sequencing of enteropathy-associated T cell lymphoma (EATL) tumors and paired normals, as well as RNA-sequencing of EATL tumors: including (1) 69 exome capture, paired-end Illumina Hiseq sequencing, BAM files from EATL tumor samples, (2) 36 exome capture, paired-end Illumina Hiseq sequencing, BAM files from EATL paired normal samples, and (3) 32 RNAseq, paired-end Illumina Hiseq sequencing, BAM files from EATL tumor samples. Illumina HiSeq 2500;ILLUMINA 137
EGAD00001003283 Whole genome sequencing data for MMML (healthy cell_line) 24
EGAD00001003282 Analysis scripts and output 37
EGAD00001003281 Genomic alterations driving tumorigenesis result from the interaction of environmental exposures and endogeneous cellular processes. With a diversity of risk factors including viral infection, carcinogenic exposures and metabolic diseases, liver cancer is an ideal model to study these interactions. Whole genome sequencing of liver tumors identified 10 mutational signatures showing distinct relationships with environmental exposures, replication and transcription. Transcription-coupled damage was specifically associated with the liver-specific signature 16 and alcohol intake. Flood of indels were identified in very highly expressed hepato-specific genes, likely resulting from replication-transcription collisions. Reconstruction of sub-clonal architecture revealed mutational signature evolution during tumor development exemplified by the vanishing of aflatoxin-B1 signature in African migrants. These findings shed new light on the natural history of liver cancers. Illumina HiSeq 2000;ILLUMINA 52
EGAD00001003280 NextSeq 550;ILLUMINA 16
EGAD00001003279 RNA sequencing data for 170 medulloblastoma tumor samples Illumina HiSeq 2000;ILLUMINA 171
EGAD00001003278 Whole Exome and Target Sequencing Data in 75 Samples from 5 Hepatocellular Carcinoma Patients. The sequencing was performed by Illumina HiSeq 4000. Background and aims: Intratumoral heterogeneity (ITH) challenges identifying mutations with target therapy potential whereas circulating cell-free DNAs (cfDNAs) could reflect nearly the entire mutation spectrum in given tumors. We investigated how to minimize the limit of ITH for profiling hepatocellular carcinoma (HCC).Methods: Thirty-two multi-regional HCC samples from five patients were subjected to whole exome sequencing (WES) and targeted deep sequencing (TDS). ITH extent was measured by the average percentage of non-ubiquitous mutations (present in parts of tumor regions). Matched cfDNAs were also analyzed by WES and TDS. Profiling efficiencies of single tumor specimen and cfDNA were compared and the one better depicted mutational landscape was selected to screen therapeutic targets.Results: We found variable extents of ITH in HCCs and observed branched and parallel evolution patterns. ITH level decreased at higher sequencing depth of TDS than that measured by WES (28.1% vs 34.9%, P < 0.01) but it remained unchanged upon additional samples analyzed. TDS of single tumor specimen detected an average of 70% the total mutations in HCC. Although more mutations were detected in cfDNA under TDS than WES, an average of 47.2% total HCC mutations uncovered by cfDNA suggested tissue outperform cfDNA and the latter may serve as alternative in profiling HCC genome. Consequently, TDS of single tumor tissue in 66 patients and cfDNAs in four unresectable HCCs identified 38.6% (26/66 and 1/4) patients bearing therapeutic targets.Conclusions: TDS of single tumor specimen could largely circumvent ITH to uncover mutations indicative of target therapy in HCC. Illumina HiSeq 4000;ILLUMINA 124
EGAD00001003276 Whole genome sequencing data for MMML (24 tumor/control pairs), fastq-files Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 49
EGAD00001003275 Targeted resequencing of samples was done with TruSeq custom amplicon low input kit (TSCA-LI, Illumina). The oligo capture probes were designed to include a prefix of 8 random nucleotides at the 5 end of each probe. The assay is designed such that each targeted locus is annealed with two probes, resulting in amplicons tagged with unique molecular identifiers (UMI) (22) of 16 bases. Raw FASTQ sequencing files were processed as following: (a) The first 8 bases were trimmed from each read and recorded with the corresponding base quality scores (BQ) in the attribute field. (b) Reads were aligned with BWA. (c) First round of PCR duplicate cleaning was performed with picard tools markDuplicates using the parameters BARCODE_TAG=BC TAGGING_POLICY=All REMOVE_DUPLICATES=true (d) Since in the previous step only duplicate reads with identical UMIs were removed, a second pass of filtering was done. Reads with identical mapping were considered unique only if their corresponding UMIs were different in at least 3 positions (i.e., UMI edit distance > 2). (e) Paired-end read pairs overlapping genomic positions were clipped to avoid overestimation of the sequencing coverage using bamUtils clipOverlap. NextSeq 550;ILLUMINA 74
EGAD00001003274 Whole genome sequencing data for MMML (tumor/control pairs and one cell_line) 315
EGAD00001003273 Low-coverage whole genome sequencing for the establishment of genomewide copy number alterations in pleura effusions and respective primary tumors Illumina MiSeq;ILLUMINA 20
EGAD00001003272 March 2017 data update (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500;ILLUMINA 8
EGAD00001003271 WGS of 23 patients diagnosed with NKTL. The tumor samples were sequenced with Illumina HiSeq 2500 platform and the resulting FASTq files have been uploaded. Illumina HiSeq 2000 (ILLUMINA) 23
EGAD00001003270 ICGC DCC Release 24, PACA-CA Whole Genome sequence merged alignments 95
EGAD00001003269 High-coverage WGS sequencing of DNA samples from 90pairs GCs was performed on the Illumina HiSeq X Ten System. Illumina HiSeq 2000;ILLUMINA 1,332
EGAD00001003268 HGSC cases in the OvCaRe and CRCHUM Tumour Banks were selected according to the following criteria: (i) were administered platinum taxane based therapy; (ii) relapsed within 12 months (365 days) or had at least longer than 4.5 years (1642.5 days) follow-up data; (iii) had at least 50% tumour content by H&E staining and expert pathology review. All cases were re-reviewed by expert pathologists to confirm the diagnosis of HGSC. Germline BRCA1 and BRCA2 was determined for all patients through hereditary cancer screening programs. The design of cases selection as a discovery cohort was engineered to amplify biological differences by selecting cases from the extremes of the outcome distribution. All HGSC tumours are primary tumour samples. Library construction and sequencing Frozen specimens with >50% tumour cellularity (based on initial slide review) were used for cryosectioning and subsequent nucleic acid extraction. Patient tumour and normal blood samples derived from primary, untreated fresh frozen tumour specimens harvested at diagnosis during standard of care debulking surgery. Germline DNA was provided from peripheral blood buffy coat on all specimens except 13 from Tokyo, where non-cancer frozen tissue was used as a germline source. DNA extraction from both matched normal (blood) and tumour samples (frozen tissue) were performed using the QIAamp Blood and Tissue DNA kit (Qiagen) and quantified using a Qbit fluorometer and reagents (high-sensitivity assay). Three lanes of Illumina HiSeq 2500 v4 chemistry for normal samples and five lanes for tumour samples were obtained. The PCR-free protocol was adopted to eliminate the PCR-induced bias and improve coverage across the genome. Illumina HiSeq 2000;ILLUMINA 118
EGAD00001003267 For GCT cohorts, OvCaRe cases were reviewed, including frozen material, by at least two expert gynecopathologists prior to inclusion in the sequencing cohort who provided the confirmation on final selected cohort. Frozen H&E from Tokyo were also used for evaluation along with representative H&E photos and review done at the Jikei School of Medicine. All GCT tumours are primary tumour samples. Library construction and sequencing Frozen specimens with >50% tumour cellularity (based on initial slide review) were used for cryosectioning and subsequent nucleic acid extraction. Patient tumour and normal blood samples derived from primary, untreated fresh frozen tumour specimens harvested at diagnosis during standard of care debulking surgery. Germline DNA was provided from peripheral blood buffy coat on all specimens except 13 from Tokyo, where non-cancer frozen tissue was used as a germline source. DNA extraction from both matched normal (blood) and tumour samples (frozen tissue) were performed using the QIAamp Blood and Tissue DNA kit (Qiagen) and quantified using a Qbit fluorometer and reagents (high-sensitivity assay). Three lanes of Illumina HiSeq 2500 v4 chemistry for normal samples and five lanes for tumour samples were obtained. The PCR-free protocol was adopted to eliminate the PCR-induced bias and improve coverage across the genome. Illumina HiSeq 2000;ILLUMINA 20
EGAD00001003266 For ENOC cohorts, OvCaRe cases were reviewed, including frozen material, by at least two expert gynecopathologists prior to inclusion in the sequencing cohort who provided the confirmation on final selected cohort. Frozen H&E from Tokyo were also used for evaluation along with representative H&E photos and review done at the Jikei School of Medicine. For ENOC, DAH985 and DG1288 are recurrent and both were treated with chemotherapy after their first surgery. DAH123 is a untreated sample, metastasis from an primary endometrial tumour. All HGSC, GCT, CCOC and the rest ENOC tumours are primary tumour samples. Library construction and sequencing Frozen specimens with >50% tumour cellularity (based on initial slide review) were used for cryosectioning and subsequent nucleic acid extraction. Patient tumour and normal blood samples derived from primary, untreated fresh frozen tumour specimens harvested at diagnosis during standard of care debulking surgery. Germline DNA was provided from peripheral blood buffy coat on all specimens except 13 from Tokyo, where non-cancer frozen tissue was used as a germline source. DNA extraction from both matched normal (blood) and tumour samples (frozen tissue) were performed using the QIAamp Blood and Tissue DNA kit (Qiagen) and quantified using a Qbit fluorometer and reagents (high-sensitivity assay). Three lanes of Illumina HiSeq 2500 v4 chemistry for normal samples and five lanes for tumour samples were obtained. The PCR-free protocol was adopted to eliminate the PCR-induced bias and improve coverage across the genome. Illumina HiSeq 2000;ILLUMINA 58
EGAD00001003265 For CCOC cohorts, OvCaRe cases were reviewed, including frozen material, by at least two expert gynecopathologists prior to inclusion in the sequencing cohort who provided the confirmation on final selected cohort. Frozen H&E from Tokyo were also used for evaluation along with representative H&E photos and review done at the Jikei School of Medicine. All CCOC tumours are primary tumour samples. Library construction and sequencing Frozen specimens with >50% tumour cellularity (based on initial slide review) were used for cryosectioning and subsequent nucleic acid extraction. Patient tumour and normal blood samples derived from primary, untreated fresh frozen tumour specimens harvested at diagnosis during standard of care debulking surgery. Germline DNA was provided from peripheral blood buffy coat on all specimens except 13 from Tokyo, where non-cancer frozen tissue was used as a germline source. DNA extraction from both matched normal (blood) and tumour samples (frozen tissue) were performed using the QIAamp Blood and Tissue DNA kit (Qiagen) and quantified using a Qbit fluorometer and reagents (high-sensitivity assay). Three lanes of Illumina HiSeq 2500 v4 chemistry for normal samples and five lanes for tumour samples were obtained. The PCR-free protocol was adopted to eliminate the PCR-induced bias and improve coverage across the genome. Illumina HiSeq 2000;ILLUMINA, Illumina Genome Analyzer II;ILLUMINA 70
EGAD00001003264 ICGC DCC Release 24, PACA-CA Exome sequence 190
EGAD00001003263 ICGC DCC Release 24, PACA-CA Deep KRAS sequencing 82
EGAD00001003262 High-coverage WES sequencing of DNA samples from 50 PTCs was performed on the Illumina HiSeq 2500 or 4000 System Illumina HiSeq 2000;ILLUMINA 100
EGAD00001003261 These are seven sequencing files form whole exome and whole genome of five tissue samples collected from one pancreatic cancer patient HiSeq X Ten;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 5
EGAD00001003260 The cell lines in this study are a combination of internally sequenced (cosmic) and externally sequenced cell lines known to be “double-wild-type” (lacking BRAF and NRAS somatic mutations). These sequences were realigned in this data set for consistency. 22
EGAD00001003259 Regions of common inter-individual DNA methylation differences in human monocytes – potential function and genetic basis WGBS Data of Samples: 43_Hm03_BlMo_Ct, 43_Hm02_BlMo_Ct, 43_Hm05_BlMo_Ct, 43_Hm01_BlMo_Ct For details about sequencing or sample metadata check http://deep.dkfz.de/ Illumina HiSeq 2000;ILLUMINA 4
EGAD00001003255 Transcriptome of anaplastic meingiomas Illumina HiSeq 2500;ILLUMINA 34
EGAD00001003254 R&D project to develop low input library construction methods. Illumina HiSeq 2500;ILLUMINA 12
EGAD00001003253 Targeted gene screen of cell line tumour samples for testing the new V2 Colorectal gene panel. Illumina HiSeq 2000;ILLUMINA 57
EGAD00001003252 Sequencing of drug resistant organoids Illumina HiSeq 2000;ILLUMINA 36
EGAD00001003250 1cm biospies of from patients undergoing bladder cystectomy will be collected. The underlying muscle and stroma will be removed and the remaining epithelia dissected into small sequential areas which will be sent for ultra-deep exome sequencing using a panel of known cancer and viral genes. Sequence analysis using similar methods to Martincorena I et al (Science 2015, 348:880) will provide an idea of the somatic mutational landscape in these patient samples. Individual patient muscle samples will also be sequenced as a reference. Illumina HiSeq 2000;ILLUMINA 55
EGAD00001003248 A BRAF V600E colorectal organoid which is sensitive to MAP kinase inhibition was mutagenised with the chemical mutagen ENU and then drug selected using a combination of Trametinib, Dabrafenib and Cetuximab. Single cell derived organoids were then manually picked and expanded in drug. Resistance was confirmed in a 14 day assay and DNA was collected. These then underwent targeted amplicon-based sequencing to confirm candidate resistance effectors from a screen in 2 2D BRAF V600E colorectal cell lines. Pools of resistant clones were also sequenced. Illumina MiSeq;ILLUMINA 36
EGAD00001003247 Liberal variant calls generated with VarScan 37
EGAD00001003246 Whole exome sequencing of hepatosplenic T cell lymphoma (HSTL) tumors, paired normals, and cell lines, including (1) 68 exome capture, paired-end Illumina Hiseq sequencing, BAM files from HSTL tumor samples, (2) 20 exome capture, paired-end Illumina Hiseq sequencing, BAM files from HSTL paired normal samples, and (3) 2 exome capture, paired-end Illumina Hiseq sequencing, BAM files from HSTL cell lines. Illumina HiSeq 2500;ILLUMINA 90
EGAD00001003245 We aim to sequence the small RNAs of 22 human melanoma cell lines in biological triplicate in order to define the microRNAs expression profile of each cell line. The data will be correlated to the mutation status and the sensitivity to a panel of drugs in order to identify genes whose deregulation is associated to drug resistance This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ Illumina HiSeq 2500;ILLUMINA 66
EGAD00001003244 We aim to sequence the mRNA transcriptome of 22 human melanoma cell lines in biological triplicate in order to define the gene expression profile of each cell line. The data will be correlated to the mutation status and the sensitivity to a panel of drugs in order to identify genes whose deregulation is associated to drug resistance This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ Illumina HiSeq 2000;ILLUMINA 66
EGAD00001003242 This study comprises of three different datasets. 1) 57 samples from the 1243 canapps cell line study,2) 91 FFPE normal samples and 3) 87 samples from the SCORT WS2 dataset. The aim is to sequence these 235 samples in order to test the new V2 Colorectal bait design. Illumina HiSeq 2000;ILLUMINA 92
EGAD00001003241 Toxoplasmosis is a zoonotic disease caused by a ubiquitous protozoan parasite called Toxoplasma gondii, which can infect all mammal and bird species throughout the world. seroprevalence varies widely between countries. Studies have estimated that between 7-34% of people in the UK have been infected with T. gondii. The vast majority of these people will not have noticed any symptoms, however about 10% of people develop a mild to moderate self limiting flu-like illness. Following the acute active stage of the infection the parasite persists in the body in the form of cysts, particularly in heart and skeletal muscle and nervous system tissues, for many years, and usually for life. In immunocompetent persons these cysts do not pose a health risk. We will use RNA-seq to quantify the transcriptional response of macrophages to T gondii infection. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ Illumina HiSeq 2000;ILLUMINA 18
EGAD00001003240 Study of cell lineage and embryogenesis using biopsy samples from sites across the whole body (post mortem). Sample donors are recruited sensitively through the Phoenix study and consent to samples being taken after their death for both the Phoenix study and this WTSI study. HiSeq X Ten;ILLUMINA 33
EGAD00001003239 This study involves mutagenizing C32, a melanoma cell line, with ENU to identify those mutations which engender resistance to a targeted treatment. Illumina HiSeq 2000;ILLUMINA 80
EGAD00001003237 Primary mucosal melanomas (MMs) arise from melanocytes located in mucosal membranes lining the respiratory, gastrointestinal and urogenital tracts. MMs frequently present late and have a poor prognosis; the 5-year survival rate is only 14%. MM makes up only ~1.4% of all melanomas and it is this rarity that makes knowledge of the genetic changes that contribute to its pathogenesis limited to a small number of exome/genome studies and other targeted studies. Thus to investigate the somatic alterations and mutation spectra in MM genomes, we have extracted genomic DNA from formalin-fixed, paraffin-embedded (FFPE) human MMs, and subjected them to whole exome sequencing. Given the propensity of MM to metastasize, we will also be sequencing metastatic MM lesions; primary and metastatic lesions from the same individual represent an excellent opportunity to identify potential drivers of metastasis in MM. Finally we will sequence 'normal' DNA from the same individual, where possible, to exclude germline variations. Illumina HiSeq 2000;ILLUMINA 141
EGAD00001003236 Raw whole genome sequence data(fastq) for the GATCI project HiSeq X Ten;ILLUMINA 10
EGAD00001003235 Raw exome sequence data(fastq) for the GATCI project unspecified;ILLUMINA 172
EGAD00001003234 Aligned whole genome sequence from AML relapse project 33
EGAD00001003231 Poly A transcriptome sequence of mutifocal hepatocelular carcinoma Illumina HiSeq 2000;ILLUMINA 7
EGAD00001003230 Small RNA expression profiles of the blood plasma-derived exosomes from B-cell chronic lymphocytic leukemia patients Illumina HiSeq 2000;ILLUMINA 3
EGAD00001003227 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: OV-AU. 146
EGAD00001003225 ICGC prostate UK study batches 4-6 prostatectomy analysis. Whole genome sequenced normal (blood) and malignant tissue pair of 111 patients. Illumina HiSeq 2000;ILLUMINA 221
EGAD00001003224 we collected tumor samples and adjacent nomal mucosae from 17 patients with colorectal cancer in surgical operation from 2014 to 2016 in the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) and the Research Institute of Surgery, Third Military Medical University (Chongqing, China). the qualified captured library of each sample was then loaded on Illumina HiSeq 2000 (Illumina, San Diego, CA) platforms and subjected to high-throughput sequencing. Illumina HiSeq 2000;ILLUMINA 34
EGAD00001003223 we collected tumor samples and adjacent nomal mucosae from 5 patients with colorectal cancer in surgical operation from 2014 to 2016 in the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) and the Research Institute of Surgery, Third Military Medical University (Chongqing, China). the qualified captured library of each sample was then loaded on Illumina HiSeq 2000 (Illumina, San Diego, CA) platforms and subjected to high-throughput sequencing. Illumina HiSeq 2000;ILLUMINA 10
EGAD00001003222 Aligned, merged and deduplicated BAM files from HiSeqXTen sequencing of six samples: matched tumour-normal pairs from three melanoma patients. 6
EGAD00001003221 Aligned, merged and deduplicated BAM files from BGISeq-500 sequencing of six samples: matched tumour-normal pairs from three melanoma patients. 6
EGAD00001003220 Whole genome, whole exome, and custom panel sequencing of high-grade meningioma cohort 188
EGAD00001003218 There are 80 Brain cancer cases (160 samples)in this study and belong to GBM-CN project. Illumina HiSeq 2000;ILLUMINA 80
EGAD00001003217 Targeted resequencing at high depth (21 genes, 9 chromosomal regions): at least 4 FFPE samples per case and matched germline DNA: * 100 cases with detailed outcome data, including 15 cases with tumour relapse (515 samples) * 40 cases with matched pre-chemotherapy biopsies (240 samples) * 50 nephrogenic rests matched to above cases (50 samples) We expect a proportion (possibly 10%) of cases to be mutationally silent on the above studies, and propose to subsequently carry out integrated whole-genome, methylome and transcriptome studies on matched frozen tissue from these cases Illumina HiSeq 2500;ILLUMINA 35
EGAD00001003216 Whole genome sequencing of tumour normal pairs of human undifferentiated sarcomas. HiSeq X Ten;ILLUMINA 98
EGAD00001003215 This data set contains whole exome sequences of individuals with self-stated parental relatedness from the East London Genes & Health cohort. Rare frequency functional variants in these healthy individuals will be studied with respect to the genetic health of the participants and loss-of-function analysis of human genes. Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 1,702
EGAD00001003213 The olfactory gene repertoire is largely species-specific, shaped by the nature and necessity of chemosensory information for survival in each species' niche. We are intrigued by this interspecific variation and started to investigate the olfactory transcriptome in primates for evidence of selection at the level of receptor gene choice. Having collected this data from two primates, we now wish to extend the analysis to humans. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ Illumina HiSeq 2500;ILLUMINA 9
EGAD00001003212 We aim to provide a powerful reference set for genome-wide association studies (GWAS) in African populations. Our pilot study to sequence 100 individuals each from Fula, Jola, Mandinka and Wollof from the Gambia to low coverage has been completed - this first part of the main effort will make available low coverage WGS data for 400 individuals from multiple ethnic groups in Burkina Faso, Cameroon, Ghana and Tanzania. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ HiSeq X Ten;ILLUMINA 74
EGAD00001003211 Deep (>25x mean coverage) whole genome sequencing on 5-10 families drawn from the Scottish Family Health Study with four or more children. HiSeq X Ten;ILLUMINA 57
EGAD00001003210 Whole genome sequencing data for MMML (cell_line) 8
EGAD00001003208 Whole genome sequencing data for MMML (12 tumor/control pairs) Illumina HiSeq 2000;ILLUMINA 25
EGAD00001003207 Whole genome sequencing data for MMML (28 tumor/control pairs) 56
EGAD00001003206 BACKGROUND TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). METHODS Multiregion high-depth whole-exome sequencing (M-seq) was performed on 100 early stage NSCLC tumors resected prior to systemic therapy. A total of 327 tumor regions were sequenced and analyzed to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between ITH and recurrence-free survival (RFS). RESULTS Widespread ITH was observed for both somatic copy number alterations (median 48% [0.03-88%]) and mutations (median 30% [0.5-93%]). Driver mutations in EGFR, MET, BRAF and TP53 were almost always clonal. However, heterogeneous driver alterations occurring later in evolution were found in over 75% of tumors and were common in PIK3CA, NF1 and genes involved in chromatin modification and DNA response and repair. Genome doubling and ongoing dynamic chromosomal instability (CIN), illustrated by mirrored subclonal allelic imbalance, were identified as causes of ITH resulting in parallel evolution of driver copy number events, including amplifications of CDK4, FOXA1, and BCL11A. Elevated copy number heterogeneity was associated with shorter RFS (HR=4.9, P=0.00044), which remained significant in a multivariate analysis. CONCLUSIONS ITH mediated through CIN, rather than point mutational heterogeneity, was associated with increased risk of relapse, supporting its value as a prognostic predictor, and the need to target this high-risk phenotype. 427
EGAD00001003205 160 WES and 25 WGS for HBV related HCC, and 15 WES for ICC belongs LICA-CN Illumina HiSeq 2000;ILLUMINA 402
EGAD00001003204 Understanding how cells sense and respond to their environment, and how these responses are modulated by genetic variation, are fundamental biological problems, particularly for understanding how pathogenic organisms invade and manipulate the cells of the human immune system. Macrophages recognize and respond to many important human pathogens including HIV-1, Mycobacteria tuberculosis and Salmonella. This study will focus on the cellular response of human macrophages to Salmonella infection and how this response is modulated by the genetic bacground of the individual as well as additional pro-inflammatory stimulus (interferon-gamma priming). We will acquire 100 human induced pluripotent stem cell lines from the HipSci project, differentiate the cells in vitro into macrophages and expose them to four environmental conditions: (i) no stimulation, (ii) interferon-gamma (18h), (iii) Salmonella typhimurium SL1344 (5h), (iv) interferon-gamma (18h) + Salmonella (5h).Subsequently, we will isolate RNA from the samples for sequencing. Illumina HiSeq 2500;ILLUMINA 236
EGAD00001003203 Aligned (hg19) sequencing data from 16 participants with FL/DLBCL. 37
EGAD00001003200 Files from whole exome sequencing of 26 tumors and two matched normals from one melanoma patient. The 26 tumors include the untreated primary, cutaneous metastases and distant metastases to internal organs. Illumina HiSeq 2500;ILLUMINA 28
EGAD00001003196 Amplicon-based fungal metagenomic sequencing for the identification of fungal species in brain tissue from Alzheimer's disease. The study consists in 14 samples, sequenced using Illumina's paired-end technology. Illumina MiSeq;ILLUMINA 14
EGAD00001003194 This dataset contains whole exome sequence of six HCC patients from Qidong China who are very likely exposed to aflatoxin. Illumina HiSeq 2500 (ILLUMINA) 12
EGAD00001003193 Exome sequencing for 2 infertile brothers Illumina HiSeq 2500;ILLUMINA 2
EGAD00001003189 Whole genome sequencing of 8 HER2-Positive Breast Cancer (in complement to EGAD00001001844) Illumina HiSeq 2000;ILLUMINA 16
EGAD00001003188 Variants and genotypes called in 50 danish parent-offspring trios from 80x Illumina sequencing data using BayesTyper. Data was produced using different insert size libraries of the sizes 180, 500, 800, 2000, 5000, 10000 and 20000 bp. The sample IDs for the fathers and mothers are TrioID-01 and TrioID-02, respectively, and the IDs for the children are TrioID-0x, where x is a number between 3 and 7 150
EGAD00001003187 TBD Complete Genomics;COMPLETE_GENOMICS 9
EGAD00001003186 Variants on the Y chromosome for 62 danish males in VCF format from the GenomeDenmark Phase 2 cohort. Variants were called using reference based approaches such as the haplotype-caller module from GATK and using alignment of denovo assemblies to the reference using ASMvar. 68
EGAD00001003181 HipSci - Bardet-Biedl Syndrome - RNA Sequencing - October 2016 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 37
EGAD00001003180 HipSci - Monogenic Diabetes - RNA Sequencing - October 2016 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 35
EGAD00001003176 For each subject, genomic DNA from whole blood, circulating cell free DNA and tumor tissues (whenever possible) were performed targeting next generation sequencing on Illumina Miseq or Hiseq 4000 platforms. The sequencing results of whole blood were used to distinguish germline and somatic mutations. Specimens were collected from patients with different kinds of solid tumors, but most are lung cancer patients. Illumina MiSeq;ILLUMINA, Illumina HiSeq 4000;ILLUMINA 1,845
EGAD00001003174 There are 116 liver cancer cases in this study and belong to LICA-CN project Illumina HiSeq 2000;ILLUMINA 232
EGAD00001003168 The blood samples of eight lung cancer patients and one benign lung tumor patient are collected for this dataset. Blood samples were centrifuged first at 1,600 × g for 10 minutes, and then the plasma was transferred into new micro tubes and centrifuged at 16,000 × g for another 10 minutes. The plasma was collected and stored at -80⁰C. CfDNA was extracted from 5 ml plasma using the Qiagen QIAamp Circulating Nucleic Acids Kit and quantified by Qubit 3.0 Fluoromter (Thermo Fisher Scientific). Bisulfite conversion of cfDNA was performed by using EZ-DNA-Methylation-GOLD kit (Zymo Research). After that, Accel-NGS Methy-Seq DNA library kit (Swift Bioscience) was used to prepare the sequencing libraries. The DNA libraries were then sequenced with 150bp paired-end reads. HiSeq X Ten;ILLUMINA 9
EGAD00001003164 Variant call set (vcf) for three (primary and two recurrent) tumors 3
EGAD00001003163 Whole genome sequencing data of 20 carcinosarcomas. Illumina HiSeq 2000;ILLUMINA 23
EGAD00001003162 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: PACA-CA. 298
EGAD00001003161 HipSci - Bardet-Biedl Syndrome - Exome Sequencing - October 2016 Illumina HiSeq 2500;ILLUMINA 38
EGAD00001003160 Exome data from patients and parents with DONSON mutations Illumina HiSeq 2000;ILLUMINA 15
EGAD00001003159 Bam files consisting of aligned MeDIP-seq reads from cord blood cells and cord blood mononuclear cells of twins not conceived through in vitro fertilisation Illumina Genome Analyzer II;ILLUMINA 105
EGAD00001003158 Bam files consisting of aligned MeDIP-seq reads from cord blood cells and cord blood mononuclear cells of twins conceived through in vitro fertilisation Illumina Genome Analyzer II;ILLUMINA 75
EGAD00001003157 Alignment of Genome Denmark Phase II dataset to GRCh38. The dataset consists of 150 Danish individuals (50 trios) sequenced to 80X. The BAM-file contains data from multiple libraries created from one individual with libraries of 180, 500, 800, 2000, 5000, 10000 and 20000 bp. The libraries were created using standard Illumina protocols for paired end reads (180-800bp libraries) and mate pair libraries (2kb-20kb). 150
EGAD00001003156 WGS files for SJMDS paper titled 'Genomic Landscape of Pediatric Myelodysplastic Syndromes' Illumina HiSeq 2000 (ILLUMINA) 4
EGAD00001003155 WES files for SJMDS paper titled 'Genomic Landscape of Pediatric Myelodysplastic Syndromes' Illumina HiSeq 2000 (ILLUMINA) 6
EGAD00001003154 RNA-Seq files for SJOS study Illumina HiSeq 2000;ILLUMINA 14
EGAD00001003153 Sequencing of untreated pancreatic cancer metastases and primary tumor sections. Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 49
EGAD00001003152 Microfluidic direct library preparation (DLP) single-cell whole-genome BAM files for near-diploid immortalized breast epithelial cell line 184-hTERT-L2. Illumina HiSeq 2500;ILLUMINA 192
EGAD00001003151 Bulk whole-genome BAM files for 184-hTERT-L2, SA501X3F, and SA501X4F. Illumina HiSeq 2500;ILLUMINA 3
EGAD00001003150 Microfluidic direct library preparation (DLP) single-cell whole-genome BAM files for fourth-passage patient-derived primary triple-negative breast cancer xenograft SA501X4F. Illumina HiSeq 2500;ILLUMINA 384
EGAD00001003149 Microfluidic direct library preparation (DLP) single-cell whole-genome BAM files for third-passage patient-derived primary triple-negative breast cancer xenograft SA501X3F. Illumina HiSeq 2500;ILLUMINA 384
EGAD00001003148 Microfluidic direct library preparation (DLP) single-cell whole-genome BAM files for near-diploid immortalized lymphoblastoid cell line GM18507. NextSeq 500;ILLUMINA 192
EGAD00001003145 Sensory neurons are nerve cells that are activated by sensory input such as heat, light and convey information to the brain. Although a key cell type in complex organisms, human sensory neurons are challenging to study because they are impossible to obtain from living donors. We have collaborated with the Neucentis Pharmaceutical Research Unit to differentiate sensory neuron like cells from human induced pluripotent stem cells derived as part of the Human Induced Pluripotent Stem Cells Initiative. We will sequence RNA from 100 IPS lines derived from healthy individuals and perform RNA-seq on the differentiated cells to identify noncoding variants that alter gene expression in human sensory neurons. Illumina MiSeq;ILLUMINA, Illumina HiSeq 2000;ILLUMINA 123
EGAD00001003143 Total stranded TruSeq RNA sequencing by Illumina of six tumor samples from six cases of pediatric Pilocytic astrocytoma. The data is published in the following paper: Tomic TT, Olausson J, Wilzen A, Sabel M, Truve K, Sjogren H, Dosa S, Tisell M, Lannering B, Enlund F, Martinsson T, Aman P, Abel F. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. PLoS One. 2017 Apr 27;12(4):e0175638. Illumina HiScanSQ;ILLUMINA 6
EGAD00001003142 RNA sequencing of 31 patient-derived fibroblast cell lines from patients with inborn errors of cobalamin (vitamin B12) metabolism, and 7 control samples. The RNA seq library was prepared using the TruSeq Stranded Total RNA Sample Preparation Kit (Illumina RS-122–2301) including Ribo-Zero Gold depletion to remove ribosomal RNA. Sequencing was done via llumina Hi-Seq2000 sequencer, using 100bp paired end reads. Illumina HiSeq 2000 (ILLUMINA), Illumina HiSeq 1500 (ILLUMINA) 38
EGAD00001003141 List of SNPs, and their frequencies, extracted from a low pass whole genome sequencing of 3,514 individuals. 1
EGAD00001003140 We analyzed the spectrum and clinical significance of MYC and BCL2 mutations in 347 DLBCL cases from population-based cohort of BC, Canada. Illumina MiSeq;ILLUMINA 347
EGAD00001003139 Aligned sequence data for 124 CPCGene Tumour/Normal Pairs from the 200PG Study 262
EGAD00001003138 A dataset consisting of Multi-regional Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) data for 54 samples from 9 patients with hepatocellular carcinoma. The dataset includes 45 tumor samples and 9 normal blood samples. Selected somatic variants were validated by Sequenom. Patients covered are: Patient 1, Patient 2, Patient 3, Patient 4, Patient 5, Patient 6, Patient 7, Patient 8, Patient 9 and Patient 10. Illumina HiSeq 2500;ILLUMINA 54
EGAD00001003137 Metastatic and primary tumour samples were collected from 4 patients with advanced breast cancer. Samples were collected at autopsy and also from biopsies taken during life. Tumour and germline samples are available. Whole exome sequencing was performed on all samples. 52
EGAD00001003135 DATA FILES FOR GRUBER SJAMLM7 RNASEQ Illumina HiSeq 2000;ILLUMINA 86
EGAD00001003134 DATA FILES FOR GRUBER SJAMLM7 EXOME Illumina HiSeq 2000;ILLUMINA 114
EGAD00001003133 RRBS data of 86 Ewing patients (French). Illumina HiSeq 2000/2500 (Fastq files available). Sheffield et al. Nat Med. 2017 Jan 30 Illumina HiSeq 2000;ILLUMINA 86
EGAD00001003132 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: GACA-CN. 84
EGAD00001003131 The dataset consists of two main sample groups. 1) The inter-tumour sample group contains a total of 97 samples from 27 patients. Each patient has a single normal and primary sample as well as one or more metastases. All samples were sequenced using IonTorrent PGM and a custom colorectal cancer (CRC) panel. 2) The intra-tumour sample group contains a total of 68 samples from a single tumour as well as a normal tissue sample. All 68 samples were sequenced using IonTorrent PGM and a custom CRC panel. Shallow whole genome sequencing was additionally applied to 10 of the samples using Illumina HiSeq 4000. Ion Torrent PGM;ION_TORRENT, Illumina HiSeq 4000;ILLUMINA 193
EGAD00001003130 Whole exome sequencing data for patients with Bosma arhinia microphthalmia syndrome (BAMS). The dataset includes 21 samples from 7 families with BAMS; see Gordon et al, Nature Genetics, 2017. Illumina HiSeq 2500;ILLUMINA, Illumina HiSeq 4000;ILLUMINA 21
EGAD00001003128 Exome sequencing data for medulloblastoma tumor/control pairs 35
EGAD00001003127 WGS data of medulloblastoma tumor/control pairs. 482
EGAD00001003126 WGS data of medulloblastoma tumor/control pairs. 74
EGAD00001003125 WGS data of medulloblastoma tumor/control pairs. 224
EGAD00001003122 December 2016 data update (bam/fastq for WGBS on samples CEMT0062, CEMT0068, CEMT0072, CEMT0086, CEMT0087) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500;ILLUMINA 5
EGAD00001003121 Dataset is composed of FASTQ files from 165 samples of small round cell sarcomas which were RNA-sequenced (whole transcriptome) with either Illumina HiSeq 2500 (120 million reads per sample, paired-end 100 pb) or Illumina NextSeq 500 (110 million reads per sample, paired-end 150) Illumina HiSeq 2500;ILLUMINA, NextSeq 500;ILLUMINA 165
EGAD00001003120 We used WGS (Complete Genomics) to characterise five metastatic tumours from a BRAF mutant melanoma patient who presented intrinsic resistance. Complete Genomics;COMPLETE_GENOMICS 6
EGAD00001003119 TP53 targeted panel aligned reads consisting of BAM paired end reads from ovarian cancer tumor samples Data Access Committee Illumina MiSeq;ILLUMINA 76
EGAD00001003118 Targeted capture sequencing for cases with MDS who were subjected to unrelated bone marrow transplantation via Japan marrow donor program 797
EGAD00001003117 In this study, we sequenced three NUT midline carcinoma genomes and their transcriptomes (NMC1, NMC2 and Ty-82), and two paired normal blood samples (for NMC1 and NMC2). Whole-genome sequencing libraries were generated by PCR-free methods, and sequencing run was made in HiSeq X machines. Transcriptome (mRNA) sequencing was performed in HiSeq 2500 machines. PCR duplicates-marked, indel-realigned, and base-recalibrarted BAM files are provided in our dataset. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 8
EGAD00001003116 Benchmark data set containing five tumor/normal pairs of non-small cell lung cancer (NSCLC) patients. Tissue pairs were screened with bisulfite (BS) sequencing, MeDIP methylation enrichment sequencing and RNA sequencing in order to identify differentially methylated and expressed spots in the genomes. Illumina HiSeq 2500;ILLUMINA 10
EGAD00001003115 Whole genome sequencing data of 15 French Caucasian and 10 African-Caribbean men with prostate Cancer. Illumina HiSeq 2000;ILLUMINA 50
EGAD00001003114 We collected fresh tissue from an untreated GBM (SF10281) directly from the operating room and subjected the biopsy to single-cell RNA-seq with the fluidigm C1 machine, resulting in sequencing libraries from 96 individual cells. Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003113 We collected fresh tissue from an untreated GBM (SF10679) directly from the operating room and subjected the biopsy to single-cell RNA-seq with the fluidigm C1 machine, resulting in sequencing libraries from 96 individual cells. Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003112 We collected fresh tissue from an untreated GBM (SF10592) directly from the operating room and subjected the biopsy to single-cell RNA-seq with the fluidigm C1 machine, resulting in sequencing libraries from 96 individual cells. Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003111 We collected fresh tissue from an untreated GBM directly from the operating room and subjected the biopsy to single-cell RNA-seq with the fluidigm C1 machine after selection of CD11b+ cells using magnetic beads. Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003110 We collected fresh tissue from an untreated GBM directly from the operating room and subjected the biopsy to single-cell RNA-seq with the fluidigm C1 machine after selection of CD11b+ cells using magnetic beads. Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003109 We collected fresh tissue from an untreated GBM directly from the operating room and subjected the biopsy to single-cell RNA-seq with the fluidigm C1 machine after selection of CD11b+ cells using magnetic beads. Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003108 We collected fresh tissue from an untreated GBM directly from the operating room and subjected the biopsy to single-cell RNA-seq with the fluidigm C1 machine after selection of CD11b+ cells using magnetic beads. Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003107 We collected fresh tissue from an untreated GBM directly from the operating room and subjected the biopsy to single-cell RNA-seq with the fluidigm C1 machine after selection of CD11b+ cells using magnetic beads. Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003106 Human HiC Illumina HiSeq 2000;ILLUMINA 16
EGAD00001003103 Cohort of 19 ADPKD patients characterized using long-read sequencing. The variant identification provided high sensitivity in identifying PKD1 pathogenic variants, with a diagnostic yield of 94.7%. This dataset includes all sequencing data (BAM files) of the 19 patients, in addition to their raw variants (unfiltered) obtained from the long-read sequencing as well as Sanger sequencing (VCF file). PacBio RS II;PACBIO_SMRT 19
EGAD00001003102 We sequenced the polyA+ fraction of the RNA of the leukocytes from 624 sardinian individuals with RNAseq. Prior to library preparation we added either ERCC ExFold RNA Spike-In. An average of 60M reads per samples with 51 bp paired-end reads were generated on a HiSeq 2000 (Illumina). Sequencing reads were then aligned using STAR-2.2.0c2 to the h37d5 reference genome supplemented with the ERCC spike-ins sequences. We further provided an exon-exon junction database that we generated from the GENCODE v14 annotation. In order to remove a contamination from a parallel experiment, we discarded any reads that mapped to the genomic regions of CBLB (chr3:105370773-105592330) and BCL11A (chr2:60672555-60784156). Filtered aligned reads (bam format) are shared. Illumina HiSeq 2000 (ILLUMINA) 624
EGAD00001003101 The need for a detailed catalogue of local variability for the study of rare diseases within the context of the Medical Genome Project motivated the whole exome sequencing of 267 unrelated individuals, representative of the healthy Spanish population. 267 vcf
EGAD00001003100 UKBEC 1st release of Exome data for 65 neuropathologically confirmed control individuals of European descent. Illumina HiSeq 2000;ILLUMINA 65
EGAD00001003099 RNAseq data set (Mollaoglu et al., MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition) Illumina HiSeq 2000;ILLUMINA 14
EGAD00001003098 Low-coverage sequencing data from 99 Lebanese samples Illumina HiSeq 2500;ILLUMINA 99 cram
EGAD00001003097 High-coverage sequencing data from 47 Yemenis samples HiSeq X Ten;ILLUMINA 47 cram
EGAD00001003096 As part of the International Parkinson's Disease Genomics Consortium, exomes of Parkinson's disease (PD) patients and healthy controls were sequenced to study the genetic etiology of PD. This UK cohort consists of 70 PD patients. Researchers can apply for access to fastq files for this cohort. Illumina HiSeq 2000;ILLUMINA 77 fastq
EGAD00001003092 Using sequencing and gene expression analyses, we identified a subgroup of HCA characterized by fusion of the INHBE and GLI1 genes and activation of sonic hedgehog pathway. Molecular subtypes of HCAs associated with different patients’ risk factors for HCA, disease progression, and pathology features of tumors. This classification system might be used to select treatment strategies for patients with HCA. Related Publication: Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation Nault, Jean-CharlesLaurent, Christophe et al. Gastroenterology , Volume 152 , Issue 4 , 880 - 894.e6 http://dx.doi.org/10.1053/j.gastro.2016.11.042 Illumina HiSeq 2000;ILLUMINA 21
EGAD00001003091 Genome and transcriptome sequence data from a clear cell carcinoma of ovary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003090 Genome and transcriptome sequence data from a metastatic leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003089 Genome and transcriptome sequence data from a pancreatic neuroendocrine patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003088 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003087 Genome and transcriptome sequence data from a pancreatic neuroendocrine cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003086 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003085 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003084 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003083 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003082 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003081 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003080 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003079 Genome and transcriptome sequence data from a presumed metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003078 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003077 Genome and transcriptome sequence data from a metastatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003076 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003075 Genome and transcriptome sequence data from a metastatic colon caner patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003074 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003073 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the pancreas patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003072 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003071 Genome and transcriptome sequence data from a pleural mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003070 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003069 Genome and transcriptome sequence data from a pancreatic neuroendocrine tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003068 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003067 Genome and transcriptome sequence data from a metastatic gastroesophageal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003066 Genome and transcriptome sequence data from an appendiceal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003065 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma of the palate patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003064 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003063 Genome and transcriptome sequence data from an atypical bronchial carcinoid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003062 Genome and transcriptome sequence data from an extraosseous osteosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003061 Genome and transcriptome sequence data from an adenocarcinoma of the distal esophagus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003060 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003059 Genome and transcriptome sequence data from a metastatic mullerian tumor of endometrium patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003058 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003057 Genome and transcriptome sequence data from a metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003056 Genome and transcriptome sequence data from a solitary fibrous tumors (sarcoma) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003055 Genome and transcriptome sequence data from a small bowel carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003054 Genome and transcriptome sequence data from a low-grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003053 Genome and transcriptome sequence data from an adrenocortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003052 Genome and transcriptome sequence data from a metastatic malignant peripheral nerve sheath tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003051 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003050 Genome and transcriptome sequence data from a serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003049 Genome and transcriptome sequence data from a prostate cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003048 Genome and transcriptome sequence data from a metastatic pancreatic neuroendocrine tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003047 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003046 Genome and transcriptome sequence data from a sigmoid cancer and an ampullary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003045 Genome and transcriptome sequence data from a metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003044 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003043 Genome and transcriptome sequence data from a breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003042 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003041 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003040 Genome and transcriptome sequence data from a chordoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003039 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003038 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003037 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003036 Genome and transcriptome sequence data from an ovarian adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003035 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003034 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003033 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003032 Genome and transcriptome sequence data from a metastatic gastric adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003031 Genome and transcriptome sequence data from a metastatic collecting duct kidney cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003030 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003029 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003028 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003027 Genome and transcriptome sequence data from an anaplastic myxopapillary ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003026 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003025 Genome and transcriptome sequence data from an endometrial adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003024 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003023 Genome and transcriptome sequence data from a metastatic renal cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003022 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003021 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003020 Genome and transcriptome sequence data from a low grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003019 Genome and transcriptome sequence data from a metastatic uveal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003018 Genome and transcriptome sequence data from a metastatic clear cell sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003017 Genome and transcriptome sequence data from a metastatic large cell neuroendocrine tumour of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003016 Genome and transcriptome sequence data from a metastatic ductal carcinoma of the breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003015 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003014 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003013 Genome and transcriptome sequence data from a metastatic gastric cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003012 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003011 Genome and transcriptome sequence data from a squamous cell carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003010 Genome and transcriptome sequence data from a metastatic uterine leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003009 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003008 Genome and transcriptome sequence data from a metastatic adenocarcinoma presumably of ovarian origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003007 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003006 Genome and transcriptome sequence data from a metastatic medullary thyroid cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003005 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003004 Genome and transcriptome sequence data from a glioblastoma multiforme patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003003 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003002 Genome and transcriptome sequence data from a metastatic adult granulosa cell tumour patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003001 Genome and transcriptome sequence data from a serous carcinoma of fallopian tube patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003000 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002999 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002998 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002997 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002996 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002995 Genome and transcriptome sequence data from a carcinosarcoma of the uterus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002994 Genome and transcriptome sequence data from a metastatic squamous cell carcinoma of anus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002993 Genome and transcriptome sequence data from a metastatic carcinoma of primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002992 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002991 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002990 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002989 Genome and transcriptome sequence data from a medullary thyroid cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002988 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002987 Genome and transcriptome sequence data from a metastatic endocervical adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002986 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002985 Genome and transcriptome sequence data from a adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002984 Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002983 Genome and transcriptome sequence data from a metastatic carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002982 Genome and transcriptome sequence data from a metastatic rectosigmoid adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002981 Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002980 Genome and transcriptome sequence data from a metastatic fibrolamellar hepatocelluar carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002979 Genome and transcriptome sequence data from a GI primary (prev breast cancer) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002978 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002977 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002976 Genome and transcriptome sequence data from a metastatic cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002975 Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma of unknown primary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002974 Genome and transcriptome sequence data from a metastatic gastric adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002973 Genome and transcriptome sequence data from a rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002972 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002969 Bisulfite-Seq data for 1 sample(s) Acute Lymphocytic Leukemia for precursor B cell from bone marrow, on Genome GRCh38. 3 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam
EGAD00001002968 RNA-Seq data for 2 sample(s) Acute Myeloid Leukemia for myeloid cell from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 2 fastq
EGAD00001002967 RNA-Seq data for 1 sample(s) for monocyte T=6day_RANK_M-CSF from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002966 RNA-Seq data for 1 sample(s) for monocyte T=10day_RANK_M-CSF from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002965 RNA-Seq data for 1 sample(s) for monocyte T=2day_S100A9_RANKL_M-CSF from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002964 RNA-Seq data for 1 sample(s) for monocyte T=1day_4hr_RANK from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002963 RNA-Seq data for 6 sample(s) Acute Lymphocytic Leukemia for precursor B cell from venous blood, on Genome GRCh38. 6 run(s), 6 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 6 fastq
EGAD00001002962 RNA-Seq data for 1 sample(s) Acute Myeloid Leukemia for blast cell from bone marrow, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002961 RNA-Seq data for 1 sample(s) for monocyte T=10day_S100A9_RANKL_M-CSF from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002960 RNA-Seq data for 1 sample(s) for monocyte T=6day_S100A9_RANKL_M-CSF from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002959 RNA-Seq data for 1 sample(s) for monocyte T=1day_M-CSF_S100A9_4hr_RANL from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002958 RNA-Seq data for 1 sample(s) Acute Myeloid Leukemia from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002957 RNA-Seq data for 1 sample(s) for monocyte T=2day_RANK_M-CSF from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002956 RNA-Seq data for 2 sample(s) T-cell lymphoma for helper T cell from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 2 fastq
EGAD00001002955 RNA-Seq data for 1 sample(s) for monocyte T=0day from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002954 RNA-Seq data for 1 sample(s) Acute Lymphocytic Leukemia from bone marrow, on Genome GRCh38. 1 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002953 RNA-Seq data for 8 sample(s) Acute Lymphocytic Leukemia for precursor B cell from bone marrow, on Genome GRCh38. 8 run(s), 8 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_rnaseq_analysis_crg_20140811 Illumina HiSeq 2000;ILLUMINA 8 fastq
EGAD00001002952 ChIP-Seq data for 4 sample(s) T-cell Acute Lymphocytic Leukemia from capillary blood, on Genome GRCh38. 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 4 bam,fastq
EGAD00001002951 ChIP-Seq data for 1 sample(s) for class switched memory B cell from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002950 ChIP-Seq data for 1 sample(s) for memory B cell from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002949 ChIP-Seq data for 1 sample(s) Acute Lymphocytic Leukemia for precursor B cell from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002948 ChIP-Seq data for 1 sample(s) for conventional dendritic cell from cord blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002947 ChIP-Seq data for 5 sample(s) for thymocyte from thymus, on Genome GRCh38. 17 run(s), 17 experiment(s), 17 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 5 bam,fastq
EGAD00001002946 ChIPmentation data for 2 sample(s) Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma from lymph node, on Genome GRCh38. 6 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002945 ChIPmentation data for 1 sample(s) for effector memory CD8-positive, alpha-beta T cell from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002944 ChIPmentation data for 2 sample(s) Activated B-Cell-Like Diffuse Large B-Cell Lymphoma from lymph node, on Genome GRCh38. 3 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002943 ChIPmentation data for 1 sample(s) for effector memory CD8-positive, alpha-beta T cell, terminally differentiated from venous blood, on Genome GRCh38. 5 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002942 ChIPmentation data for 2 sample(s) for regulatory T cell from venous blood, on Genome GRCh38. 13 run(s), 9 experiment(s), 9 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002941 ChIPmentation data for 1 sample(s) for mature conventional dendritic cell GM-CSF_IL4_T=6_days_R848_T=24hrs from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002940 ChIPmentation data for 1 sample(s) for conventional dendritic cell from cord blood, on Genome GRCh38. 4 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002939 ChIPmentation data for 3 sample(s) Burkitt Lymphoma from lymph node, on Genome GRCh38. 10 run(s), 8 experiment(s), 8 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002938 ChIPmentation data for 2 sample(s) T-cell Acute Lymphocytic Leukemia from capillary blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002937 ChIPmentation data for 1 sample(s) for naive B cell from tonsil, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002936 ChIPmentation data for 5 sample(s) Acute Lymphocytic Leukemia for precursor B cell from venous blood, on Genome GRCh38. 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 5 bam,fastq
EGAD00001002935 ChIPmentation data for 2 sample(s) Acute Myeloid Leukemia for blast cell from bone marrow, on Genome GRCh38. 12 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002934 ChIPmentation data for 1 sample(s) for cytotoxic CD56-dim natural killer cell from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002933 ChIPmentation data for 1 sample(s) for class switched memory B cell from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002932 ChIPmentation data for 1 sample(s) for germinal center B cell from tonsil, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002931 ChIPmentation data for 3 sample(s) Lymphoma_Follicular from lymph node, on Genome GRCh38. 7 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002930 ChIPmentation data for 1 sample(s) Acute Lymphocytic Leukemia from bone marrow, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002929 ChIPmentation data for 1 sample(s) for CD38-negative naive B cell from cord blood, on Genome GRCh38. 5 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002928 ChIPmentation data for 7 sample(s) Acute Lymphocytic Leukemia for precursor B cell from bone marrow, on Genome GRCh38. 13 run(s), 13 experiment(s), 13 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 7 bam,fastq
EGAD00001002927 ChIPmentation data for 1 sample(s) for central memory CD4-positive, alpha-beta T cell from venous blood, on Genome GRCh38. 5 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002926 ChIPmentation data for 1 sample(s) for effector memory CD4-positive, alpha-beta T cell from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002925 ChIPmentation data for 1 sample(s) for immature conventional dendritic cell GM-CSF_IL4_T=6_days from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002924 ChIPmentation data for 2 sample(s) for central memory CD8-positive, alpha-beta T cell from venous blood, on Genome GRCh38. 11 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002923 ChIPmentation data for 2 sample(s) for memory B cell from venous blood, on Genome GRCh38. 6 run(s), 4 experiment(s), 4 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002922 ATAC-seq data for 1 sample(s) for monocyte RPMI_LPS_T=4hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002921 ATAC-seq data for 1 sample(s) for monocyte RPMI_T=24hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002920 ATAC-seq data for 4 sample(s) Multiple Myeloma for plasma cell from bone marrow, on Genome GRCh38. 4 run(s), 4 experiment(s), 4 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 4 bam,fastq
EGAD00001002919 ATAC-seq data for 1 sample(s) for monocyte RPMI_T=1hr from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002918 ATAC-seq data for 5 sample(s) Mantle Cell Lymphoma from venous blood, on Genome GRCh38. 5 run(s), 5 experiment(s), 5 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 5 bam,fastq
EGAD00001002917 ATAC-seq data for 2 sample(s) for germinal center B cell from tonsil, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002916 ATAC-seq data for 106 sample(s) Chronic Lymphocytic Leukemia from venous blood, on Genome GRCh38. 111 run(s), 109 experiment(s), 109 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 106 bam,fastq
EGAD00001002915 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=24hrs_RPMI_T=5days_LPS_T=4hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002914 ATAC-seq data for 1 sample(s) for monocyte RPMI_T=6days from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002913 ATAC-seq data for 1 sample(s) for monocyte RPMI_LPS_T=1hr from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002912 ATAC-seq data for 2 sample(s) for plasma cell from tonsil, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002911 ATAC-seq data for 1 sample(s) for germinal center B cell from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002910 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=4hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002909 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=24hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002908 ATAC-seq data for 2 sample(s) for class switched memory B cell from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002907 ATAC-seq data for 2 sample(s) for osteoclast from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002906 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=1hr from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002905 ATAC-seq data for 3 sample(s) for unswitched memory B cell from venous blood, on Genome GRCh38. 3 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002904 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=24hrs_RPMI_T=5days from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002903 ATAC-seq data for 3 sample(s) for naive B cell from tonsil, on Genome GRCh38. 3 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002902 ATAC-seq data for 3 sample(s) for naive B cell from venous blood, on Genome GRCh38. 3 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002901 ATAC-seq data for 2 sample(s) for monocyte RPMI_LPS_T=24hrs_RPMI_T=5days from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002900 ATAC-seq data for 1 sample(s) for monocyte RPMI_LPS_T=24hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002899 ATAC-seq data for 1 sample(s) for monocyte RPMI_T=4hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002898 Oliocapture sequencing libraries from the study "Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study". These are sequencing libraries from the extension cohort of 277 patients. Specifically, there are 402 tumor libraries and 82 normal libraries. 484
EGAD00001002897 Whole genome sequencing libraries from the study "Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study". These are libraries from 41 patients. Specifically: 15 transformed follicular lymphoma (TFL), 6 early progressers (PFL), and 20 non-early progressers (NPFL). For TFL and PFL patients, trios consisting of diagnostic (T1), transformed/progressed (T2) and a matching normal are available (n = 63 libaries in total). For NPFL patients, a tumor-normal pair are available (n = 40 libraries). 103
EGAD00001002896 Amplicon sequencing libraries from the study "Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study". These are Illumina amplicon deep sequencing libraries (n = 118) to validate somatic predictions made in the whole genome sequencing libraries. Specifically, there are 72 tumor libraries and 46 normal libraries. Some patients may have multiple amplicon libraries sequenced. Illumina HiSeq 2000;ILLUMINA 118
EGAD00001002893 This dataset contains all RNA-seq runs for the BLN panel of cell lines and matched parental tumors. Tumor/cell line pairs have been authenticated using SNP profiles and all pairs were confirmed. Please note: The dataset also contains raw data from an early primary culture (BLN-1) where no stable cell line could be generated. Please also note different reference genomes. Illumina HiSeq 2000;ILLUMINA 21
EGAD00001002892 The data contains genome sequencing of clear cell renal cell carcinomas and normal kidney tissues. The samples were collected from patients from different European countries. Illumina HiSeq 1000;ILLUMINA 21 fastq
EGAD00001002891 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002890 Exome sequencing of 96 French-Canadians 102
EGAD00001002886 Exome sequencing of North American Brain Expression Consortium (NABEC) subject. Illumina HiSeq 2000;ILLUMINA 298 fastq
EGAD00001002885 Raw sequence data, fastq format Illumina HiSeq 2000;ILLUMINA 26 fastq
EGAD00001002884 RNAseq on Illumina HiSeq2000/2500 of PDO culture derived from colorectal cancer metastasis sample at early/late passages Illumina HiSeq 2000;ILLUMINA 8
EGAD00001002883 RNAseq on Illumina HiSeq2000/2500 of Patient-derived xenograft derived from colorectal cancer sample of a validation cohort of 60 PDX Illumina HiSeq 2000;ILLUMINA 60
EGAD00001002773 As part of the International Parkinson Disease Genomics Consortium, exomes of Parkinson disease (PD) patients and healthy controls were sequenced to study the genetic etiology of PD. The Dutch cohort consists of 175 patients with a young age of onset below 50 years. Researchers can apply for access to fastq files for this cohort. Illumina HiSeq 2000;ILLUMINA 211 fastq
EGAD00001002772 In this study we characterized genomic alterations in three bladder cancer patients with metastatic disease courses. Multiple regions were procured by laser microdissection or punctures from primary tumor, lymph node metastases and from distant metastases. Data provided here consist of 35 Bam files for WES (32 Tumors and 2 blood, 1 adjacent normal) NextSeq 500;ILLUMINA 35 bam
EGAD00001002771 Modified alignments based on a single sample, each with different characteristics 61 bam
EGAD00001002770 A KNIH011 miRNA-seq single end data for podocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002769 A KNIH010 miRNA-seq single end data for podocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002768 A KNIH009 miRNA-seq single end data for preadipocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002767 A KNIH008 miRNA-seq single end data for adipocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002766 A KNIH007 miRNA-seq single end data for adipocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002765 A KNIH006 miRNA-seq single end data for beta cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002764 A KNIH005 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002763 A KNIH004 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002762 A KNIH003 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002761 A KNIH002 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002760 A KNIH001 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002759 A KNIH011 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for podocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002758 A KNIH010 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for podocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002757 A KNIH009 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for preadipocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002756 A KNIH008 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for adipocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002755 A KNIH007 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for adipocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002754 A KNIH006 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for beta cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002753 A KNIH005 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002752 A KNIH004 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002751 A KNIH003 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002750 A KNIH002 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002749 A KNIH001 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002748 DDD DATAFREEZE 2014-11-04: 4293 trios - exome sequence CRAM files 12,548 cram,bam
EGAD00001002747 Whole-exome sequencing (WES) of 216 breast cancer metastasis-normal pairs from patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA or MOSCATO prospective trials (France). Illumina HiSeq 2500;ILLUMINA, NextSeq 500;ILLUMINA, Illumina HiSeq 4000;ILLUMINA 432
EGAD00001002746 Illumina HiSeq 2000;ILLUMINA 13 bam
EGAD00001002745 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 7 fastq
EGAD00001002744 RNA sequencing data of human small intestinal macrophage subtypes NextSeq 500;ILLUMINA 15
EGAD00001002743 These samples comprise both melanoma cases and controls sequenced for a selection of loci linked to disease susceptibility. These bams are a subset of the sequencing restricted specifically to the GRCh37 coding areas of the BAP1 gene. 3,186 bam
EGAD00001002742 Whole-genome sequencing data from Chad and Lebanon. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 15 cram
EGAD00001002741 Additional Xenograph files for PCGP SJERG Illumina HiSeq 2000;ILLUMINA 11 bam
EGAD00001002740 We propose to definitively characterise the somatic genetics of breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing. Illumina MiSeq;ILLUMINA, Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 164
EGAD00001002739 Aligned sequence data from 14 Prostate cancer samples with BRCA2 mutations 49 bam
EGAD00001002738 Background: In follicular lymphoma (FL), studies addressing the prognostic value of microenvironment-related immunohistochemical (IHC) markers and tumor cell-related genetic markers have yielded conflicting results, precluding implementation in practice. Therefore, the Lunenburg Lymphoma Biomarker Consortium (LLBC) performed a validation study for published markers. Methods: To maximize sensitivity, an end-of-spectrum design was applied for 122 uniformly immunochemotherapy-treated FL patients retrieved from international trials and registries; early failure (EF): progression or lymphoma-related death <2 years versus long remission: response duration of >5 years. IHC staining for T-cells and macrophages was performed on tissue microarrays from initial biopsy and scored with a validated computer-assisted protocol. Shallow whole-genome and deep targeted sequencing was performed on the same samples. Results: 96/122 cases with complete molecular and immunohistochemical data were included in the analysis. EZH2 wild-type (p=0.006), gain of chromosome 18 (p=0.002), low percentages of CD8+ cells (p=0.011) and CD163+ areas (p=0.038) were associated with EF. No significant differences in other markers were observed, thereby refuting previous claims on their prognostic significance. Conclusion: Using an optimized study design, this LLBC study validates wild-type EZH2 status, gain of chromosome 18, low percentages of CD8+ cells and CD163+ area as predictors of EF to immunochemotherapy in FL. Illumina HiSeq 2000;ILLUMINA 96
EGAD00001002736 WES of human: A mutation in VPS15 (PIK3R4) causes a ciliopathy and affects IFT20 release from the cis-Golgi WES (Agilent SureSelect All Exon XT2 50 Mb kit) has been realized on three affected siblings (II.1, II.3, II.5) and one healthy sister (II.4). Raw data (BAM files) are provided: - II.1.aligned.sorted.dedup.realign.recal.bam - II.3.aligned.sorted.dedup.realign.recal.bam - II.5.aligned.sorted.dedup.realign.recal.bam - II.4.aligned.sorted.dedup.realign.recal.bam Illumina HiSeq 2500; 4 bam
EGAD00001002735 mRNA, total RNA, small noncoding RNA, NOMe-Seq and DNase-Seq data from following samples (not every Sequencing Type for every sample): 01_HepG2_LiHG_Ct1 41_Hf01_LiHe_Ct 41_Hf02_LiHe_Ct 41_Hf03_LiHe_Ct 51_Hf03_BlCM_Ct 51_Hf04_BlCM_Ct 51_Hf03_BlEM_Ct 51_Hf04_BlEM_Ct 51_Hf03_BlTN_Ct 51_Hf04_BlTN_Ct Metadata available at deep.dkfz.de Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 10
EGAD00001002734 Whole Genome Sequencing data set for the study "Premalignant SOX2 in ovarian cancer patients" Complete Genomics (COMPLETE_GENOMICS) 39
EGAD00001002733 Gene expression was analyzed for stem/progenitor cell types and terminally differentiated cell types of the human blood lineage (HSC, MPP, CMP, GMP, CLP, MLP0, MLP1, MLP2, MLP3). Illumina HiSeq 4000;ILLUMINA 13 bam
EGAD00001002732 DNA methylation was analyzed for stem/progenitor cell types and terminally differentiated cell types of the human blood lineage (HSC, MPP, CMP, MEP, GMP, CLP, MLP0, MLP1, MLP2, MLP3, MK, CD4+ Tcell, CD8+ Tcell, Bcell, NK, Neut, Mono). Illumina HiSeq 4000;ILLUMINA 63 bam
EGAD00001002731 whole exome sequencing of tumor- as well as PBMC-derived DNA of five melanoma patients for identification of naturally presented patient-specific neoepitopes Illumina HiSeq 2000;ILLUMINA 10
EGAD00001002730 SPEED - childhood dystonia KMT2B dataset Illumina HiSeq 2000;ILLUMINA 5
EGAD00001002729 Haplotype Reference Consortium Release 1.1 - subset for release via the EGA 11,227 other,vcf,readme_file,tabix,vcf_aggregate
EGAD00001002728 In this dataset, exome sequencing of bone marrow samples taken during multiple timepoints of disease progression from 13 AML patients are present. These samples were take either before/after treatment, at diagnosis or at relapse. Illumina HiSeq 1500;ILLUMINA, Illumina HiSeq 2500;ILLUMINA, Illumina Genome Analyzer IIx;ILLUMINA 32
EGAD00001002727 1,591 single cells from 11 colorectal cancer patients were profiled using Fluidigm based single cell RNA-seq protocol to characterized cellular heterogeneity of colorectal cancer. 630 single cells from 7 cell lines were profiled similarly to benchmark de novo cell type identification algorithms. Illumina HiSeq 3000;ILLUMINA 2,221
EGAD00001002726 Cluster headache is a relatively rare headache disorder, typically characterized by multiple daily, short-lasting attacks of excruciating, unilateral (peri-)orbital or temporal pain associated with autonomic symptoms and restlessness. To better understand the pathophysiology of cluster headache, we used RNA sequencing to identify differentially expressed genes and pathways in whole blood of patients with episodic (n = 19) or chronic (n = 20) cluster headache in comparison with headache-free controls (n = 20). Illumina HiSeq 4000;ILLUMINA 60
EGAD00001002725 Autism spectrum disorder (ASD) is a collection of neuro-developmental disorders characterized by deficits in social interaction and social communication, along with restricted and repetitive behaviour patterns. we globally interrogated the histone acetylomes of enhancers in a large cohort of ASD and control samples by analyzing tissue from three brain regions postmortem: prefrontal cortex (PFC), temporal cortex (TC) and cerebellum (CB). H3K27ac was selected as the representative acetylation mark and 288 ChIP-seq were performed on these postmortem samples. Illumina HiSeq 2000;ILLUMINA 291 bam
EGAD00001002724 September 2016 data update (bam/fastq/vcf) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500;ILLUMINA 24 fastq,vcf,bam
EGAD00001002722 Exome sequencing for 26 patients with matched blood RNA-seq for 41 patients Illumina HiSeq 2500;ILLUMINA 93 fastq
EGAD00001002721 Whole genome sequencing of 300 individuals from 142 diverse populations Illumina HiSeq 2000;ILLUMINA 21 bam
EGAD00001002719 This dataset contains whole-genome sequencing data files from colon organoid cultures, which were mutated using CRISPR-Cas9 for specific genes (APC, KRAS, TP53 and SMAD4) to generate in vitro transformed cancer cells. After introducing each mutation, the resulting cultures were subjected to whole-genome sequencing. In addition, some cultures were xenotransplanted in recipient mice. The resulting primary tumors and corresponding metastases were subjected to whole-genome sequencing. HiSeq X Ten;ILLUMINA 15 bam
EGAD00001002718 In this study we characterized genomic alterations in two to five metachronous bladder tumors from 29 patients initially diagnosed with early stage disease. Fourteen patients (32 tumors) had non progressive disease (NPD) and 15 patients (34 tumors) had progressive disease (PD). Whole exome sequencing (WES, ~50x mean read depth and whole transcriptome RNA-seq was performed (RNA was not advalible for 4 tumors). Data provided here consist of 71 mapped Bam files form whole transcriptome RNA-seq. Illumina HiSeq 2000;ILLUMINA 71 bam
EGAD00001002717 In this study we characterized genomic alterations in two to five metachronous bladder tumors from 29 patients initially diagnosed with early stage disease. Fourteen patients (32 tumors) had non progressive disease (NPD) and 15 patients (34 tumors) had progressive disease (PD). Whole exome sequencing (WES, ~50x mean read depth and whole transcriptome RNA-seq was performed (RNA was not advalible for 4 tumors). Data provided here consist of 71 unmapped Bam files form whole transcriptome RNA-seq. Illumina HiSeq 2000;ILLUMINA 71 bam
EGAD00001002716 In this study we characterized genomic alterations in two to five metachronous bladder tumors from 29 patients initially diagnosed with early stage disease. Fourteen patients (32 tumors) had non progressive disease (NPD) and 15 patients (34 tumors) had progressive disease (PD). Whole exome sequencing (WES, ~50x mean read depth and whole transcriptome RNA-seq was performed (RNA was not advalible for 4 tumors) Data provided here consist of 122 Bam files for WES (83 Tumors and 39 blood) Illumina HiSeq 2000;ILLUMINA 122 bam
EGAD00001002715 Exome sequencing of isolate populations and Generation Scotland Illumina HiSeq 2000;ILLUMINA 1,027 bam
EGAD00001002714 We recruited 100 healthy, male donors of self-reported European descent (EUB) and 100 of self-reported African descent (AFB) (Ghent, Belgium). For each participant, peripheral blood mononuclear cells (PBMCs) were isolated from whole blood on Ficoll-Paque density gradients. Monocytes were then positively selected with magnetic CD14 microbeads and exposed for 6 hours to different ligands activating TLR4 (LPS), TLR1/2 (Pam3CSK4), TLR7/8 (R848) and to a human seasonal influenza A virus (IAV). High-quality RNA was obtained from unstimulated and stimulated monocytes for 970 of the 1000 samples (200 x 5 conditions), and was sequenced on an Illumina HiSeq2000. On average, 34 million 101-bp single-end reads were obtained per sample. Illumina HiSeq 2000;ILLUMINA 970 fastq
EGAD00001002713 DNase accessibility data for BLUEPRINT consortium immune cells included in eFORGE software tool Illumina HiSeq 2000;ILLUMINA 25 fastq,bam,readme_file
EGAD00001002712 ChIP-Seq_H3K27me3 data for 131 mature neutrophil sample(s). 321 run(s), 134 experiment(s), 134 analysis(s) on human genome GRCh37. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/protocols/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 131 fastq,cram,bam
EGAD00001002711 ChIP-Seq_H3K4me3 data for 133 mature neutrophil sample(s). 208 run(s), 136 experiment(s), 136 analysis(s) on human genome GRCh37. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/protocols/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 133 fastq,cram,bam
EGAD00001002710 ATAC-seq data for 4 sample(s) from bone marrow, on Genome GRCh38. 4 run(s), 4 experiment(s), 4 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 4 bam,fastq
EGAD00001002709 ATAC-seq data for 136 sample(s) from venous blood, on Genome GRCh38. 141 run(s), 139 experiment(s), 139 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 136 bam,fastq
EGAD00001002708 ATAC-seq data for 7 sample(s) from tonsil, on Genome GRCh38. 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 7 bam,fastq
EGAD00001002707 Whole exome sequencing of a normal sample, primary tumor sample, and relapse tumor sample of a transformed non-Hodgkins follicular lymphoma patient with extraordinary response to treatment. Illumina HiSeq 2000;ILLUMINA 3 fastq
EGAD00001002705 McGill EMC Release 6 data Illumina HiSeq 2500;ILLUMINA 343 fastq
EGAD00001002704 DATA FILES FOR MULLIGHAN MEF2D RNASEQ UNSTRANDED Illumina HiSeq 2000;ILLUMINA 217 bam
EGAD00001002698 Recurrent breast cancer is almost universally fatal. We characterize 170 patients locally relapsed or distant metastatic cancers using massively parallel sequencing. We identify that the relapse-seeding clone disseminates late from the primary tumor. TP53 and AKT1 appear to be enriched in ER-positive cancers predisposed to relapse. Mutation acquisition continues at relapse as the same mutation signatures continue to operate and new signatures, such as that caused by radiotherapy appear de novo. In 49% of cases we identify drivers mutations private to the relapse and these are sampled from a wider range of cancer genes, including SWI-SNF complex and JAK-STAT signaling. Illumina MiSeq;ILLUMINA, Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 387 cram
EGAD00001002697 Recurrent breast cancer is almost universally fatal. We characterize 170 patients locally relapsed or distant metastatic cancers using massively parallel sequencing. We identify that the relapse-seeding clone disseminates late from the primary tumor. TP53 and AKT1 appear to be enriched in ER-positive cancers predisposed to relapse. Mutation acquisition continues at relapse as the same mutation signatures continue to operate and new signatures, such as that caused by radiotherapy appear de novo. In 49% of cases we identify drivers mutations private to the relapse and these are sampled from a wider range of cancer genes, including SWI-SNF complex and JAK-STAT signaling. Illumina HiSeq 2000;ILLUMINA 9 bam
EGAD00001002696 Recurrent breast cancer is almost universally fatal. We characterize 170 patients locally relapsed or distant metastatic cancers using massively parallel sequencing. We identify that the relapse-seeding clone disseminates late from the primary tumor. TP53 and AKT1 appear to be enriched in ER-positive cancers predisposed to relapse. Mutation acquisition continues at relapse as the same mutation signatures continue to operate and new signatures, such as that caused by radiotherapy appear de novo. In 49% of cases we identify drivers mutations private to the relapse and these are sampled from a wider range of cancer genes, including SWI-SNF complex and JAK-STAT signaling. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2000;ILLUMINA 60 bam,cram
EGAD00001002693 Innate immune memory is the phenomenon whereby innate immune cells such as monocytes or macrophages undergo functional reprogramming after exposure to microbial components such as LPS. We apply an integrated epigenomic approach to characterize the molecular events involved in LPS-induced tolerance in a time dependent manner. ChIP-seq, RNA-seq, WGBS and ATAC-seq data were generated. This analysis identified epigenetic programs in tolerance and trained macrophages, and the potential transcription factors involved. Experimental set-up Time-course in vitro culture of human monocytes. Two innate immune memory states can be induced in culture through an initial exposure of primary human monocytes to either LPS or BG for 24 hours, followed by removal of stimulus and differentiation to macrophages for an additional 5 days. Cells were collected at baseline (day 0), 1 hour, 4 hour, 24 hour and 6 days. unspecified;, Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2000;, NextSeq 500; 71 fastq,bam
EGAD00001002692 DATA FILES FOR MULLIGHAN MEF2D RNASEQ STRANDED Illumina HiSeq 2000;ILLUMINA 200 bam
EGAD00001002691 RNAseq data for 10 patients: 10 tumors and 10 cell lines NextSeq 500;ILLUMINA 20
EGAD00001002690 Exome sequencing of for 10 patients: 10 tumors, 10 cell lines and 7 blood samples (for 3 patients blood was not available) Illumina HiSeq 2000; 27 bam
EGAD00001002689 ICGC Oesophageal Adenocarcinoma tissue samples Illumina HiSeq 2000; 10 bam
EGAD00001002687 CD4 T-Cell RNA-Seq Illumina HiSeq 2000;ILLUMINA 4
EGAD00001002686 CD4 T-Cell ChIP-Seq Illumina HiSeq 2000;ILLUMINA 42
EGAD00001002685 Breast cancer PDTX sequencing data from Bruna et al, Cell 2016 - Exome Sequencing - Shallow Whole Genome Sequencing - RRBS Methylation Sequencing Illumina HiSeq 2500;ILLUMINA, Illumina HiSeq 2500; 393 bam
EGAD00001002684 Whole genome sequencing of 98 tumour-normal pairs for the PAEN-AU pancreatic neuroendocrine cancer project. 196 bam
EGAD00001002683 A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases 22 bam
EGAD00001002682 BLUEPRINT DNA methylation profiles of T cells in type 1 diabetes-discordant monozygotic twins Bisulfite-Seq 8 bam
EGAD00001002681 RNA-seq, ChIP-seq, and ATAC-seq files for PCGP SJERG paper titled "Deregulation of DUX4 and ERG in acute lymphoblastic leukemia" Illumina HiSeq 2000 (ILLUMINA) 53
EGAD00001002680 This dataset contains RNA-Seq files for the SJACT cohort associated with the paper "Genetic landscape of pediatric Adrenocortical Tumor". In this paper, we analyse 37 adrenocortical tumours (ACTs) by whole-genome, whole-exome and/or transcriptome sequencing. Illumina HiSeq 2000;ILLUMINA 26 bam
EGAD00001002679 This dataset contains WES files for the SJACT cohort associated with the paper "Genetic landscape of pediatric Adrenocortical Tumor". In this paper, we analyse 37 adrenocortical tumours (ACTs) by whole-genome, whole-exome and/or transcriptome sequencing. Illumina HiSeq 2000; 38 bam
EGAD00001002678 The data set consists of low-pass whole genome sequence data of single CTCs, pools of CTCs and germline controls for a cohort of 31 SCLC patients at both baseline, and for 5 patients at relapse. In addition 9 CDX models and associated germline controls (where available) are included. Illumina MiSeq;ILLUMINA, Illumina HiSeq 2500;ILLUMINA, NextSeq 500;, NextSeq 500;ILLUMINA 319 fastq
EGAD00001002677 DATA FILES FOR PCGP SJERG (WXS) Illumina HiSeq 2000;ILLUMINA 42 bam
EGAD00001002676 DATA FILES FOR PCGP SJERG (WGS) Illumina HiSeq 2000;ILLUMINA 44 bam
EGAD00001002675 RNA-Seq data for 205 mature neutrophil sample(s). 205 run(s), 205 experiment(s), 205 analysis(s) on human genome GRCh37. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/protocols/README_rnaseq_analysis_sanger_20160816 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 205 bam,fastq
EGAD00001002674 RNA-Seq data for 197 CD14-positive, CD16-negative classical monocyte sample(s). 197 run(s), 197 experiment(s), 197 analysis(s) on human genome GRCh37. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/protocols/README_rnaseq_analysis_sanger_20160816